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Abstract
Extracellular vesicles (EVs), which are nanoscale vesicles secreted by cells into biofluids, are
of research interest due to their roles in intercellular communication. EVs released from
mesenchymal stromal cells (MSCs) have tremendous potential in cell-free regenerative
medicine, while EVs released from diseased cells are being studied as biomarkers for
minimally invasive and early disease detection. Presented in this thesis are gold nanohole
arrays for the capture and sensitive detection of EVs by surface-enhanced Raman spectroscopy
(SERS), a plasmonic technique capable of single molecule detection. Herein, we have
characterized EVs released from MSCs and ovarian cancer cells, with a focus on cell lines that
have been underexplored by SERS in literature. Using a hybrid principal component analysismachine learning approach, we have demonstrated the platform’s potential in classifying EV
groups with high (~ 99 %) accuracy, sensitivity, and specificity, which we hope will one day
translate to point-of-care detection for disease diagnosis.
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Summary for Lay Audience
The fields of rehabilitative and diagnostic medicine are constantly evolving, where the former
is seeking safer and more effective ways to repair tissue and organ damage, and the latter is
developing methods for rapid, non-invasive, and early disease detection. One area of research
with applications in both these fields is extracellular vesicle (EV)-based technology. EVs are
a complex group of membrane-bound vesicles released from cells into biofluids including
blood, saliva, and urine. EVs are traditionally separated into three subclasses based on
attributes such as size, biomolecular cargo, and mechanisms of formation and release. The
most interesting subclasses of EVs consist of exosomes and microvesicles since they play roles
in intercellular communication. Released from mesenchymal stromal cells (MSCs), EVs have
shown immense promise in cell-free regenerative and restorative applications, while EVs
released from diseased cells (e.g., cancer cells) are studied for their applications as disease
biomarkers. However, the nanoscale size and molecular heterogeneity of EVs pose a
significant research problem since sensitive methods are required for their detection.
Surface-enhanced Raman spectroscopy (SERS) is a sensitive, non-destructive plasmonic
technique that has shown potential in biosensing applications, including EV detection. The
highly sensitive nature of SERS is based on the collective oscillation of free electrons at a
nanoscale, metallic surface. Consequently, large electromagnetic fields are produced at the
edges of the nanoscale features, and analytes that are confined to these regions experience
significant enhancement with respect to their Raman signal intensity. Proposed in this work
are gold nanohole arrays for the capture and SERS characterization of EVs. The SERS spectra
gathered provide insight into the biochemical composition of EVs, and EVs from both MSCs
and ovarian cancer cells are explored. SERS characterization of EVs from the specific cell
sources investigated in this thesis have been largely underexplored in literature, and so the
work presented here is novel. Statistical analysis is utilized to find patterns in the complex
spectra acquired, and machine learning is further implemented to classify EVs from various
cell sources. The high (~ 99 %) accuracies, sensitivities, and specificities reported in this thesis
demonstrate great promise for translation to clinical testing.
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General Introduction

Extracellular vesicles (EVs) are complex, membrane-bound, nanoscale vesicles that are
secreted by nearly all cells into human biofluids. EVs play an important role in intercellular
signaling and communication by the transfer of proteins and RNA to near and distant cells.
There is a strong research interest in EVs since they have high potential as non-invasive
disease biomarkers, may additionally offer prognostic information in a variety of diseases,
and can be used in therapeutic applications. Discussed in this introductory chapter are the
classification of EVs in terms of size, contents, and biogenesis as well as current detection
methods and their limitations. Nanoplasmonic techniques for EV characterization, which
are used extensively throughout this thesis, are also introduced in this chapter.

1.1 EV Background
Interestingly, the concept of minute-sized cell derivatives dates back approximately 150
years to Darwin’s pangenesis theory.[1] This theory postulated that every cell type in the
human body generates small particles called gemmules which communicate to other cell
types through the transfer of molecules and may also mediate the maternal-fetal transfer of
heritable information. Although this theory was not accepted at the time due to lack of
experimental evidence, scientists today can relate the concept of Darwin’s gemmules to
EVs that indeed carry nucleic acid and protein cargo of their parent cell,[2,3] and also
mediate maternal-fetal dialogue.[4]
Although historically thought of as carriers of cell waste, EVs have long been implicated
in cell development,[5] intercellular signaling,[6] cellular stress responses,[7] and cell
maturation.[8] Early work in EV research in 1969 recognized gene expression via EVs and
their functional roles when EVs were found to be associated with epiphyseal cartilage
matrix calcification in mice.[5] Around the same time, EVs were identified in the periaxonal
space within the mouse atrium and a model was proposed for neuronal signaling.[6] Half a
decade later, early evidence of the association of EVs with mechanisms for cellular stress
was uncovered.[7] In the 1980s, it was observed sheep reticulocytes shed their transferrin
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receptors by releasing EVs during maturation and it was theorized that EV secretion was a
mechanism for the removal of membrane components no longer need during reticulocyte
maturity.[8,9] These findings, however, were misinterpreted, leading to the misidentification
of EVs as simply a means of the disposal of unwanted cellular components or cellular
waste.[10]
Nearly three decades after EVs were first identified, serious work in elucidating EV
signaling functions began to be published, and EVs were finally established as intercellular
communication agents. In 1996, it was observed that B-cells from both humans and mice
secrete EVs carrying the major histocompatibility class-II (MHC-II) molecule initiated Tcell responses.[11] Later studies further reported EV-associated signaling activities such as
enhancing cell proliferation, survival, adhesion, and chemotaxis.[12] Multiple studies in
2006 through 2008 elucidated EV nucleic acid cargo and determined that EV-derived
RNAs were transferrable to recipient cells,[13-15] leading to the exponential increase in EV
research over the past decade.

1.1.1

Overview of EV Classification

EVs are secreted by nearly all cell types and are found in biofluids including blood, urine,
breast milk, cerebrospinal fluid, amniotic fluid, and ascites.[16] EVs are generally separated
into three subclasses: apoptotic bodies, microvesicles, and exosomes (Figure 1-1).
Multiple factors are considered when dividing extracellular vesicles into these three
subclasses, including size, chemical and biomolecular composition, biogenesis, and
mechanism of formation.[17] Apoptotic bodies are the largest subclass of EVs in terms of
their size distribution, as they typically have a diameter range of 1 – 5 μm.[18] Apoptotic
bodies are formed, as their name suggests, from cells in the late stages of apoptosis, and
are released by directly budding from the cell’s plasma membrane.[17] They typically
contain cytosolic contents including proteins, RNA, and fragmented DNA, as well as
cellular organelles.[19] Microvesicles, like apoptotic bodies, are also released by directly
budding from the plasma membrane.[20] However, microvesicles are not released by cells
undergoing apoptosis, so they are more interesting to researchers in their roles in
intercellular communication. Microvesicles are also smaller than apoptotic bodies as their
diameter range is approximately 100 – 1000 nm.[17] Microvesicles also contain contents
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that are reflective of their parent cell and carry surface markers (e.g., integrins and
selectins), cytosolic proteins, lipids, and nucleic acids such as messenger RNAs (mRNAs),
microRNAs (miRNAs), circular RNAs (circRNAs) and long noncoding RNAs
(lncRNAs).[21] Exosomes are the smallest subclass of EVs in terms of size with a diameter
range of approximately 30 – 150 nm.[18] Exosome cargo and content is similar to
microvesicles, albeit with distinct surface markers such as tetraspanins CD9, CD63, and
CD81,[22] and their main distinction is in their biogenesis. Exosomes do not bud directly
from the plasma membrane, but are rather released following the fusion of multivesicular
bodies (MVBs) with the plasma membrane.[23] MVBs contain intraluminal vesicles (ILVs),
which once expelled from the cell, are termed exosomes. Alternatively, ILVs may fuse
with lysosomes for the degradation of their content.
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Figure 1-1: (A) Schematic illustration of the three subclasses of EVs and their
biogenesis and release with (B) transmission electron microscope (TEM) images of
the three EV types for comparison. TEM images are adapted with permission from
reference [24] (copyright 2016 Elsevier B. V.).
ILVs are formed within MVBs by the invagination of late endosomal membranes. During
this process, certain proteins are incorporated into the invaginating membrane while
cytosolic contents are engulfed within the ILVs. There are two pathways that are proposed
for the mechanism of ILV formation: one that is dependent on the endosomal sorting
complex required for transport (ESCRT) function, and one that is ESCRT-independent.[25]
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A complex protein machinery made up of four separate ESCRTs (0 through III) work
together to facilitate the formation of MVBs, vesicle budding, and protein cargosorting.[26,27]
The ESCRT-dependent mechanism is initiated by the recognition and sequestration of
ubiquitinated proteins to specific domains of the endosomal membrane via the ubiquitinbinding subunits of ESCRT-0. After interaction with ESCRT-I and ESCRT-II, the total
complex combines with ESCRT-III, which is the protein complex that is involved in
promoting the budding process. The MVB membrane buds are cleaved to form ILVs and
the ESCRT-III complex separates from the membrane using energy supplied by a sorting
protein (VPS4). ESCRT components (e.g., TSG101 and CHMP4), ESCRT-associated
proteins (e.g., ALIX), and ubiquitinated proteins have been identified in exosomes
originating from various cell types, thus providing evidence for the ESCRT-dependent
pathway.[25]
The ESCRT-independent biogenesis mechanism instead depends on raft-based
microdomains for the lateral segregation of cargo within the endosomal membrane and
emphasizes the key role of exosomal lipids in exosome biogenesis. Microdomains (i.e.,
highly enriched sphingomyelinases) can form ceramides via the hydrolytic removal of the
phosphocholine moiety.[25] Ceramides induce the lateral phase separation and coalescence
of microdomains in membranes. Furthermore, the cone-shape structure of ceramides may
cause the spontaneous negative curvature of the endosomal membrane, thus promoting
domain-induced budding. The ESCRT-independent mechanism is supported by the fact
that ILVs can be formed despite silencing key subunits of all ESCRT complexes.[28,29]
Researchers warn that although it is useful to conceptualize EV biogenesis and classify
EVs by either direct plasma membrane budding or fusion of the plasma membrane with
MVBs, this is an oversimplified model that does not entirely encapsulate or explain the
complexity of EVs. Furthermore, the distinction between the two pathways is becoming
less clear as researchers discover and elucidate pathway interdependencies and cell
specialization. For example, the interdependencies of EV biogenesis pathways can lead to
EVs that biochemically and biophysically resemble an endosomally-derived EV (i.e., an
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exosome) that were produced by budding directly from the plasma membrane.[30] This
phenomenon indicates that cells can indeed specialize to operate beyond a binary
classification of EV biogenesis pathways. Furthermore, while it is conceptually simple to
classify EVs based on their size (i.e., exosomes are smaller than microvesicles, which are
smaller than apoptotic bodies), there is substantial overlap of size distributions among each
group, and there exist variations in the size distributions from author to author.
Nevertheless, the generally accepted criteria for EV classification are summarized in Table
1-1.
Table 1-1: Characterization of EVs based on their size, density, contents, biogenesis,
and mechanism of release.
Feature

Exosomes

Microvesicles

Apoptotic Bodies

Size

30 – 150 nm

100 – 1000 nm

1 – 5 μm

Content

Proteins (e.g.,

Proteins (e.g.,

Cytosolic content

CD9/63/81, ALIX,

CD154), lipids,

(proteins, RNAs,

TSG101), lipids,

RNAs (e.g., mRNAs,

fragmented DNA) and

RNAs (e.g., mRNAs,

miRNAs, lncRNAs),

cellular organelles

miRNAs, lncRNAs),

DNAs

DNAs
Mechanism

Release of ILVs

Direct outward

Plasma membrane

of Release

from MVBs

budding from the

blebbing during

following the fusion

plasma membrane

apoptosis

of MVBs with
plasma membrane

1.1.2

EVs in Intercellular Communication

EVs, specifically microvesicles and exosomes, play an important role in intercellular
signaling and communication either by transmitting information via direct contact or
through the transfer of proteins and nucleic acids,[31] and can occur by three general
mechanisms (Figure 1-2). The first mechanism involves the “docking” of secreted EVs
onto the membrane of the recipient cell via a ligand-receptor interaction. This interaction
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involves the transfer of information between cells rather than the delivery of EV cargo into
the recipient cell, and examples include immunomodulation[11,32] and morphogen
signaling.[33,34] The second mechanism involves the direct fusion of secreted EVs with the
membrane of the recipient cell, resulting in the direct uptake of proteins and nucleic acids
from the donor cell into the cytosol of the recipient cell. For example, the delivery of
mRNAs,[14] miRNAs,[35,36] lncRNAs,[37] DNAs,[38,39] and oncoproteins[40,41] by EVs has
been reported. The third mechanism, which also results in the direct uptake of donor cell
cargo, involves the ingestion of secreted EVs into the recipient cell via endocytosis.[42,43]
Endocytosis is a broad term for cellular internalization, and can occur, for example, by
phagocytosis (i.e., the secreted EV is “eaten” by the recipient cell), or be receptormediated, caveolin-mediated, or lipid raft-mediated.[44] For successful intercellular
communication to occur, particularly via receptor-mediated pathways, secreted EVs must
contain recognition molecules that will direct them to the proper target and be accepted
onto or into the recipient cell.

Figure 1-2: Schematic illustration of the three general mechanisms of intercellular
communication via EV exchange between a secreting cell and a recipient cell.

1.2 Cellular Origins
Since EVs play an important role in intercellular communication, there is strong research
interest in their therapeutic roles as well as their roles as biomarkers in disease detection,
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diagnosis, and prognosis. EVs that are released from mesenchymal stromal cells (MSCs)
are considered to be potent cell-free regenerative and curative agents.[45] EVs have also
been implicated as mediators of many cardiovascular diseases (e.g., heart failure and
obesity),[46] neurogenerative diseases (e.g., Alzheimer’s and Parkinson’s),[47] inflammatory
diseases (e.g., arthritis),[48] and musculoskeletal diseases.[49] One of the most prominent
research areas of EVs is their role as cancer biomarkers, since they have been associated
with many cancers such as ovarian,[50] prostate,[51] and breast cancer.[52]

1.2.1

Mesenchymal Stromal Cell (MSC)-Derived EVs

MSCs, which are multipotent stem cells capable of differentiating into many different cell
types, serve to maintain and repair tissues in vivo.[53] Although found in a variety of
different sources in the body, MSCs are most commonly isolated from bone marrow,
adipose tissue, and umbilical cord blood.[54] MSCs that are administered locally or
systematically can release a mixture of bioactive molecules, including EVs, which can
promote the activation of endogenous repair pathways and lead to anti-inflammatory, antiapoptotic, and restorative effects.[55,56] However, EVs isolated from MSCs can be used as
therapeutic agents by themselves, and have shown similar and even superior functional
capacities compared to MSCs. There are additionally safety advantages of administering
EVs over living cells, since EVs are non-oncogenic, less immunogenic, less toxic, and
easier to sterilize, handle, and store than living cells.[57]
MSC-derived EVs have demonstrated to be effective therapeutic agents in many conditions
and diseases. For example, EVs have been used in the therapy of lung diseases,[58] such as
pulmonary infections (including COVID-19),[59,60] asthma,[61,62] acute respiratory distress
syndrome,[63,64] idiopathic pulmonary fibrosis,[65,66] and cystic fibrosis.[67,68] In addition to
lung disease therapies, MSC-derived EVs have been implicated in tissue engineering and
many regenerative therapies.[69] In neurological regeneration, EVs have been used
following nerve crush injury,[70-72] stroke,[73,74] traumatic brain injury,[75] and spinal cord
injury.[76-78] MSC-derived EVs have also been used to improve motor function outcomes
in multiple sclerosis[79] and autoimmune encephalitis,[80] as well as to improve cognitive
function recovery in Alzheimer’s disease.[81] In the case of cardiovascular regeneration,
EVs have been used to reduce infarct size,[82] increase myocardial viability,[83] and increase
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cardiac repair[84] following myocardial ischemia/reperfusion injury. MSC-derived EVs
have also been in bone regeneration,[85-87] cartilage regeneration,[88-90] muscle
regeneration,[91-93] kidney regeneration,[94-96] and liver regeneration.[97-99] Lastly, EVs have
been used in wound healing therapies including photo-damaged dermal fibroblasts,[100]
excisional skin wounds,[101] ischemic wounds,[102] cutaneous wounds,[103] and seconddegree burns.[104]
Although the application of EVs in therapeutic and regenerative medicine is a very
interesting area of research, this thesis will focus on the development of methods for the
sensitive detection, characterization, and analysis of MSC-derived EVs. Clinical
applications of MSC-derived EVs in therapeutics is challenged by the lack of standardized
techniques for EV isolation, purification, characterization, and analysis. The topic of the
characterization of MSC-derived EVs is explored in detail in Chapter 3.

1.2.2

Cancer-Derived EVs

In 2020 alone, approximately 19.3 million new cancer cases were diagnosed globally, and
nearly 10.0 million cancer deaths occurred.[105] Cancer remains one of the leading causes
of premature death worldwide,[106] and so there is a need for the development of effective
methods for cancer treatment and prevention. During cancer development and progression,
a tumor develops for a long time at the subclinical or microscopic level before it
metastasizes; to be clinically detectable, a tumor must grow to a size of approximately 1
cm3, containing about 109 cells.[107] Since there is a high probability of prior dissemination
at the time of diagnosis, methods for early cancer diagnosis must be developed to combat
the global mortality of cancer. Since EVs have a specific profile of miRNAs, proteins, and
lipids that mirror the cargo of their parent cells, EVs can be used as biomarkers for cancer
detection, and can even be used to monitor cancer progression and drug resistance. [108,109]
EV-derived miRNAs have been identified as potential biomarkers of many different
cancers, including liver,[110] lung,[111,112] gastrointestinal,[113] colorectal,[114] pancreatic,[115]
breast,[116] and ovarian cancer,[117] as well as melanoma.[118-120] Furthermore, it has been
observed that cancer cells secrete a higher number of EVs compared to their normal or
non-malignant counterparts.[121]
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In addition to acting as cancer fingerprints, EVs are involved in a wide range of processes
involved in cancer progression, including inflammatory responses, angiogenesis,
lymphogenesis, cell migration and proliferation, immune suppression, and metastasis.[121123]

Cancer-derived EVs have also been shown to influence non-cancer cells to generate a

tumor microenvironment conducive for tumor growth by influencing endothelial cells to
support neoangiogenesis,[124] as well as metastasis by inducing vascular permeability.[125]
Furthermore, cancer-derived EVs have been shown to not only suppress immune
responses,[126] but to also modify immune cells towards pro-tumorigenic and pro-metastatic
phenotypes through the transfer of functional oncoproteins from cancerous donor cells to
recipient cells.[125,127] EV transfer of miRNAs as well as oncogenic entities (e.g., mutated
proteins, fusion gene mRNAs, and lncRNAs) from cancer cells to neighboring cells within
the tumor microenvironment can not only drive malignancy,[128] but lead to drug
resistance.[129]
Clinical translation of EV technology in cancer diagnosis, especially at the early stage, is
hindered by the lack of standardization of methods for the isolation, quantification,
characterization, and analysis of EVs, particularly from complex biofluids like blood.
Another challenge is the fact that the percentage of total blood vesicles that are cancerderived is unknown,[130] even for advanced stage cancers that are associated with the
release of a higher number of EVs compared to early stage cancers. Therefore, it is
currently unknown if a given blood sample will contain levels of cancer-derived EVs
within the range of current technological capabilities for EV detection.[121] Although EVs
are involved in many facets of cancer biology, the focus of this thesis is the sensitive
detection and characterization of EVs for early cancer diagnosis, which is the topic of
Chapter 4.

1.3 Methodologies for EV Detection and Characterization
EVs are generally characterized by at least two methods. One of these methods is a physical
characterization method to confirm that the analytes are within the acceptable size ranges
for EVs, as well as for EV enumeration and morphology. Although this is an important
study, physical characterization alone is not suitable for diagnostic studies, and so
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biochemical characterization is required. Biochemical characterization is used to determine
the surface composition of EVs as well as the composition of their cargo.

1.3.1

Common Physical Characterization Methods

Commonly used methods for EV size quantification are dynamic light scattering (DLS),
nanoparticle tracking analysis (NTA), and flow cytometry. Microscopy techniques can also
be used for EV enumeration and size quantification in addition to providing insight into
EV morphology and topography. Commonly used microscopy techniques for EV
characterization include transmission electron microscopy (TEM), scanning electron
microscopy (SEM), and atomic force microscopy (AFM).
Both DLS and NTA measure the size of particles based on their Brownian motion in
solution, the basis of which is that lighter particles will diffuse faster, and that speed is
relative to particle size.[131] In DLS, EVs are illuminated with a laser beam and the light is
scattered. The intensity changes of scattered light are recorded as a function of time, thus
allowing the Brownian motion of EVs to be observed.[132] While DLS can detect particles
as small as 10 nm in diameter, the detection of particles in a heterogenous solution is biased
towards larger particles since they scatter more light compared to smaller particles.[132]
Therefore, in a solution containing exosomes and microvesicles, the average EV diameter
calculated is more likely to be skewed towards microvesicle size. In NTA, the Brownian
motion of individual EVs is tracked and their size and total concentration is calculated
based on their mean velocity.[131] NTA can detect EVs in the range of approximately 50 –
1000 nm, which nearly encompasses the generally accepted size ranges for exosomes and
microvesicles.[133] NTA however cannot typically detect particles larger than 1000 nm in
diameter since larger particles have limited Brownian motion, and therefore move too
slowly.
Flow cytometry has been commonly used over the past couple of decades for EV analysis.
With a resolution of approximately 300 – 500 nm, depending on the setup, flow cytometry
is not as sensitive as DLS or NTA, but it is advantageous in that it offers a higher
throughput and multiple markers can be determined simultaneously.[132] Flow cytometry
operates by directing a laser beam through a stream of sheath fluid containing suspended
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EVs, which cause light scattering, similarly to DLS or NTA. At the same time, the EVs are
labelled with fluorescent dyes either in their interior or on their surface, thus providing
insight into their cellular origins.[134] Nanoscale flow cytometry (nFC) has emerged in more
recent years, following the same operating principles as conventional flow cytometry, but
capable of detecting particles as small as approximately 100 nm.[131] Additionally, nFC can
discriminate EVs from other nanoparticles or contaminants in the solution.
Electron microscopy techniques like TEM and SEM are attractive for imaging EVs since
they offer much higher resolution compared to light microscopy techniques due to the fact
that the wavelength of an electron is approximately 100 000-fold smaller than the
wavelength of a photon in visible light.[135] In TEM, stained, thin sections of a preserved
sample are imaged by passing a broad electron beam through the sample above a
fluorescent screen or charge coupled device (CCD) (Figure 1-3A).[134] The resulting twodimensional image provides insight into the internal structure of the sample. In SEM, a
focused beam of electrons is scanned across the sample surface, interacting with atoms on
the sample surface (Figure 1-3B). Secondary electrons are collected and counted by a
detector, producing a three-dimensional image containing information of the sample’s
surface topography.[134] Both TEM and SEM offer sub-nanometer resolution,[135,136] but
require laborious sample preparation when imaging biological samples like EVs, which
must be cryogenically or chemically preserved.[137] Freezing the EVs also causes them to
shrink, and so volume lost must be accounted for in order to accurately determine EV size.
Like electron microscopy techniques, AFM can offer high resolution images of EVs.
Images are generated by quantifying the forces between a probe (cantilever tip with a very
low spring constant, usually composed of silicon or silicon nitride) and the sample surface
(Figure 1-3C).[138] The cantilever scans the surface while a piezoelectric crystal raises or
lowers the cantilever to maintain constant bending. A laser beam is constantly reflected
from the top of the cantilever towards a position-sensitive photodetector, recording the
actual position of the cantilever. Since AFM ages are three-dimensional, height information
can be obtained simultaneously with lateral information, with resolutions of approximately
0.001 nm and 0.1 – 1.0 nm, respectively.[138] The tip can interact with the surface
topography of the sample either by directly tracing the sample (contact mode), oscillating
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vertically at or below its resonant frequency and gently tapping the sample surface (tapping
mode), or oscillating above the sample surface with a small amplitude at a frequency larger
than its resonant frequency (non-contact mode).[139] An advantage of AFM over TEM and
SEM is that minimal sample preparation is required for EV imaging, since scans can be
conducted in air or even in fluid, thereby mimicking the native conditions of the EVs.[137]
However, high resolution scans are very time consuming, especially when large areas are
imaged.

Figure 1-3: Schematic illustration of some high-resolution microscopic techniques for
EV characterization, including (A) TEM, (B) SEM, and (C) AFM.
Although physical characterization of EVs is important for the quantification of their size,
these methods alone are not suitable for applications such as disease diagnosis. They are
usually used to supplement such studies and confirm the presence of EVs in a given sample,
but diagnostic studies require at least one type of biochemical characterization method to
determine EV chemical composition.

1.3.2

Conventional Biochemical Characterization Methods and
their Limitations

Specific proteins can be detected by immunoblotting (IB) techniques that utilize labelled
antibodies for protein capture. For EV detection by IB, purified EVs are generally lysed to
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release their proteins. Western blotting is commonly used to confirm the presence of EVs
in a sample by detecting EV-associated surface proteins like CD9, CD63, and CD81, as
well as EV-associated cytosolic proteins like ALIX and TSG101.[134] Common protein
contaminants like apolipoproteins, albumin, and uromodulin that are often co-isolated with
EVs in complex samples (e.g., blood) can also be identified in this manner. However, IB
techniques like Western blotting are semi-quantitative, require a large sample volume, and
only allow for bulk assays, so individual EVs cannot be analyzed.[134] IB methods are
typically not used for EV diagnostic applications, but are simple ways to confirm the
presence of EVs and fulfil EV characterization guidelines outlined by the International
Society of Extracellular Vesicles (ISEV).
Mass spectrometry (MS)-based “omic” analyses such as lipidomics and proteomics have
been used for high-throughput, multiplexed EV profiling of lipids and proteins,
respectively.[10] Lipidomics involves the characterization and quantitation of lipids in
biological samples as well as lipid compositional responses of cell and organism levels to
stimuli.[140] The typical workflow involves EV lysis, lipid extraction, and the separation of
lipid species, usually by gas chromatography (GC)-MS or liquid chromatography (LC)MS.[140] Lipidomic analysis of EVs is mainly used to elucidate and understand EV
biogenesis and protein packaging pathways, but it has also recently been explored in
determining lipid-based biomarkers for disease diagnosis, prognosis, and treatment. For
example, prostate cancer cell-derived exosomes have been found to be highly enriched in
glycosphingolipids, sphingomyelin, cholesterol, and phosphatidylserine compared to their
parent cells, and such lipids could potentially be exploited as cancer biomarkers.[141]
Similarly to lipidomics, the two main goals of EV proteomic analysis include the
determination of disease-associated proteins that can be exploited as diagnostic and
prognostic biomarkers,[142] and the investigation of the roles of EVs and their proteomes in
biological processes and phenomena (e.g., disease progression).[143] Proteomic analysis
workflow is similar to lipidomic analysis in that EVs are lysed, and proteins are extracted
and fractionated (typically by LC-MS).[27] MS-based proteomic analysis that utilizes
advanced instruments allows for the rapid identification of thousands of proteins.[140]
However, analysis is complicated by contamination from high-abundant proteins found in
EV source media, as well as low EV recovery (and thus protein yield) due to losses at
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various stages of isolation, sample processing, and fractionation.[140] Although perhaps not
yet ideal for point-of-care diagnostic applications, the increased depth of EV proteomic
profiling is beneficial for the complete characterization of EV proteomes and the
understanding of their functions.
Enzyme-linked immunosorbent assay (ELISA) is commonly used and widely available for
the detection of an analyte based on the antigen-antibody reaction. In ELISA, an antibody
is linked to an enzyme, and a detectable signal like a color change is detected by a
spectrophotometer upon the addition of a substrate.[144] ELISAs are usually performed on
96-well polystyrene plates, allowing for the analysis of multiple samples per assay, and can
be performed by one of four methods: direct, indirect, sandwich, and competitive (Figure
1-4A).[144] Direct ELISA is the fastest of the four, as the target antigen is immobilized on
the well and detected with an antibody conjugated to an enzyme. In contrast, indirect
ELISA utilizes a primary antibody for antigen detection and an enzyme-coupled secondary
antibody is used to detect the primary antibody. In sandwich ELISA, the capture antibody
is coated on the well and the sample is added. Based on the detection antibody, this method
can be either direct or indirect. Lastly, in competitive ELISA, the primary antibody is
incubated with the sample antigen, and the antigen-antibody complexes are added to a plate
containing the same antigen, resulting in a competitive reaction between the sample antigen
and the antigen bound to the plate. If more antigen is present in the sample, less primary
antibody will be available to bind to the coated antigen. ELISA is a powerful tool for EV
analysis since the use of tetraspanins offers high sensitivity for EV detection. For example,
EVs derived from ovarian cancer cells can be identified based on their CD24 and EpCAM
expression.[145]
Lateral-flow immunoassay (LFIA) is another method that can be used for EV detection.
The operation principle is similar to ELISA, except the capture antibody or immobilized
antigen is bound to a membrane like nitrocellulose instead of a plastic well. Unlike
ELISAs, LFIAs can be performed in a single step and in a few minutes, thus avoiding the
tedious steps and long incubation times required for ELISA.[146] In LFIAs, four components
are integrated serially, with small overlap between components allowing for sample flow
(Figure 1-4B).[144] A small sample volume is added to a sample pad, which then migrates
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to the conjugate pad onto which the detection reagent has been conjugated. The analyte
interacts with the conjugate and both migrate to the membrane onto which the capture
reagent has been immobilized. Immunoassay formats in LFIA can vary like in ELISA, and
typically sandwich and competitive formats are selected.[147] After interaction, excess
sample and reagent migrate to the absorbent pad, which is used as storage and waste. In
the case of EVs, tetraspanins are commonly used for detection, and the LFIA platform can
even be modified into a multiple target assay by utilizing different antibodies on different
test lines,[144] thereby allowing for the detection of a broad range of EVs based on their
surface content.[148]

Figure 1-4: Schematic illustration of two common immunoassay techniques for EV
detection and characterization, including (A) ELISA, which highlights four common
detection methods, and (B) LFIA, which highlights sample flow along four main
components.
Immunoassay approaches as described above can be attractive methods for EV detection
and characterization, but there are several limitations. For example, ELISA involves
multiple wash steps that introduce ample opportunity for error, and the process is time-

17

consuming.[144] Microfluidic biosensors are currently being developed to reduce assay time
and cost of analysis, possibly rendering traditional ELISA as obsolete in the future.[149]
Although LFIA is quicker, simpler, and easier to operate than ELISA, its simplicity limits
its sensitivity, and thus its performance for point-of-care diagnostics.[144] General
limitations regarding immunoassays such as high cost, lack of automation, low sensitivity,
and low specificity can be overcome by the use of nanoplasmonic techniques.[150]

1.3.3

Nanoplasmonic Approaches for Biochemical
Characterization

Nanoplasmonics refers to the study and application of light-metal interactions at the
nanoscale.[151,152] Metals can be viewed as a plasma in which conduction electrons move
throughout the bulk material. When incident light interacts with the metal, the photons
induce a collective oscillation of free electrons in the conduction band of the metal,
producing surface plasmon polaritons (SPPs) that propagate at the metal-dielectric
interface (Figure 1-5A).[150] Nanoplasmonic biosensors are beneficial in that there is
potential for label-free quantitative analysis, a high degree of multiplexing, and potential
for miniaturization.[153] Prominent examples of nanoplasmonic techniques for biosensing
include surface plasmon resonance (SPR) sensing, SPR imaging (SPRi), localized surface
plasmon resonance (LSPR) sensing, and surface-enhanced Raman spectroscopy (SERS).
SPR occurs when the frequency of incident light matches the oscillation frequency of the
surface plasmons. A common SPR experimental setup known as the Kretschmann
configuration implements a prism tightly connected to a glass sensor chip coated with a
thin film of gold.[154,155] For biosensing, the gold film is usually covered with antibodies
for the target capture of biological analytes.[156] Analytical signals of biomolecules can then
be measured by considering the refractive index (RI) of the volume in which the surface
plasmons are travelling.[150] The resonance condition for a given plasmonic setup is
sensitive to changes in RI within a nanometer-sized length from the material. In SPR, this
area extends usually 100 – 400 nm away from the metal surface (Figure 1-5B).[156] Upon
the binding of biomolecules to the metal surface (e.g., by antigen-antibody interactions),
subtle changes in the RI lead to large observable changes in the resonance condition. Thus,
SPR is a very sensitive technique for biosensing. Although miniaturization of SPR devices

18

for clinical applications is being explored and developed, commercially available setups
are still quite bulky as well as costly.[150] Furthermore, SPR devices have limited
multiplexing capability, often requiring multiple sensor chips and multi-flow channels.[156]
As opposed to conventional SPR sensing, SPRi allows for detection and imaging in the
entire sensor area, thus providing multiplexed detection. Most SPRi devices utilize the
aforementioned Kretschmann configuration but with a CCD camera for the detection of
reflected light, allowing for real-time visualization of the chip.[154,157] However, since a less
compact optical configuration is used with less sensitive detectors, SPRi suffers from
reduced sensitivity (about one order of magnitude) compared to SPR sensing.[156]
LSPR occurs when the surface plasmon is confined to a nanoparticle surface with
dimensions that are far smaller than the wavelength of incident light.[150] LSPR is
fundamentally similar to SPR as photons of the incident light interact with metallic
nanofeatures to create a free electron oscillation in the conduction band of the metal
(Figure 1-5C). In contrast to SPR, the free electron oscillation is non-propagating, and the
electric field enhancement observed is confined much closer to the metallic surface
(approximately 10 – 30 nm).[150] Although LSPR sensing requires nanoscale probes or
substrates with nanoscale features, thereby increasing cost and complexity, LSPR offers
high surface sensitivity compared to SPR, has negative contribution from the bulk
sensitivity

and

bulk

miniaturization.[156,158]

temperature

fluctuations,
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Figure 1-5: (A) Schematic illustration of an SPP at the interface of a dielectric
material and metal surface, and (B) the strength of the resulting electric field, which
decays exponentially away from the metal surface. (C) Schematic illustration of the
LSPR of a metal nanoparticle induced by light.
The theory of LSPR is also fundamental to SERS, which is the analytical technique of
choice for EV characterization in this thesis. Although conventional Raman spectroscopy
offers high chemical specificity, is non-destructive, and inert to aqueous background, the
recorded signal is very weak (i.e., low sensitivity) and often masked by fluorescent
background, particularly in biological samples.[150] These drawbacks are overcome by
SERS, which exploits LSPR to achieve very high sensitivity (i.e., single molecule
detection).[159] The theory of Raman spectroscopy and SERS are explained in Chapter 2 of
this thesis, and several probes and substrates used in the SERS characterization of EVs are
reviewed.

20

1.4 Scope of Thesis
This thesis presents the fabrication of plasmonic gold nanohole arrays for EV capture and
subsequent EV spectral characterization and analysis by SERS. The following four
chapters are summarized below.
In Chapter 2, the theory of and instrumentation for Raman spectroscopy and SERS are
explained in detail. Further reviewed in this chapter are SERS probes and platforms that
have been proposed for EV characterization in recent years. Chapter 2 also details the
methodology and theory behind several other techniques used throughout this thesis,
including electron-beam lithography, principal component analysis (PCA), and machine
learning.
In Chapter 3, nanohole arrays fabricated for EV capture and SERS characterization are
presented and characterized in detail. Further characterized are EVs isolated from MSCs
derived from two sources (bone marrow and pancreatic tissue). The SERS signals from
these samples are further analyzed by PCA and machine learning.
In Chapter 4, the nanohole arrays presented in Chapter 3 are used again but are challenged
with a larger scale of EV samples, this time derived from ovarian cancer cells. Four ovarian
cancer cell lines are explored by SERS here and compared with the SERS signals from a
normal ovarian cell line as a control. The SERS signals from these samples are further
analyzed by PCA, and machine learning is used to discriminate the cancerous EVs from
the normal EVs.
In Chapter 5, the thesis is concluded and summarized. Also discussed in this chapter are
suggested ideas for future work.
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Chapter 2

2

Principles of EV Detection and Characterization

This chapter focuses on the fundamentals of Raman spectroscopy and SERS, the latter of
which was the main technique used throughout this thesis for EV characterization. To
simplify the analysis and characterization of EVs, PCA is used in this thesis, as well as
machine learning for the classification of various EV sources. Therefore, the fundamentals
of PCA are also discussed, and an overview of machine learning and its various algorithms
is also provided. The performance and fabrication of several SERS probes and substrates
used for EV detection in recent years, including both direct and indirect methods, are also
reviewed.

2.1 Principles of Raman Spectroscopy
Raman spectroscopy is a technique used to study the vibrational modes of a system based
on Raman scattering, a phenomenon that was observed by Raman and Krishnan in 1928.[1,2]
Photons can be elastically or inelastically scattered from an atom or molecule. When a
photon is elastically scattered from an atom or molecule, the scattered photon has an energy
that is equal in energy to the incident radiation.[3] This process is commonly referred to as
Rayleigh scattering. When a photon is inelastically scattered from an atom or molecule, the
scattered photon has an energy that is not equal to that of the incident radiation. The
inelastic scattering process is referred to as Raman scattering. Raman scattering occurs
very infrequently compared to Rayleigh scattering (approximately 1 in 107 photons).[4]
Depending on the initial vibrational state of the atom or molecule, Raman scattered photons
can be of lower or higher energy than the incident radiation (Figure 2-1).[5] A molecule in
its ground vibrational state (𝜈 = 0) can absorb a photon of energy ℎ𝜈𝑒𝑥 and reemit a photon
of energy ℎ(𝜈𝑒𝑥 − 𝜈𝑉 ). When Raman scattered photons are of lower energy than the
incident radiation, they are said to be Stokes scattered. A molecule in an excited vibrational
state (𝜈 = 1) can absorb a photon of energy ℎ𝜈𝑒𝑥 and reemit a photon of energy ℎ(𝜈𝑒𝑥 +
𝜈𝑉 ). When a scattered photon is of higher energy than the incident radiation, it is said to be
anti-Stokes scattered. At room temperature, more molecules exist in their ground
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vibrational state than an excited vibrational state, and so Stokes Raman scattering occurs
more frequently than anti-Stokes Raman scattering.[6] In both cases of Raman scattering
(±ℎ𝜈𝑉 ), the observed wavenumber or Raman shift is a direct measure of the molecule’s
vibrational energy and specific to chemical bonds in molecules (i.e., “fingerprints”).

Figure 2-1: Schematic illustration of the Rayleigh and Raman (Stokes and antiStokes) scattering processes.
Raman line intensity (𝐼𝑅 ) can be described by:[4]
𝐸𝑖

𝐼𝑅 ∝ 𝜈 4 ∙ 𝜎 ∙ 𝐼 ∙ 𝑒 − 𝑘𝑇 ∙ 𝑐

(2-1)

In Equation 2-1, 𝜈 and 𝐼 are the frequency and intensity of the incident radiation,
𝐸𝑖

respectively, 𝜎 is the Raman scattering cross-section, 𝑒 − 𝑘𝑇 is the Boltzmann factor for state
𝑖, and 𝑐 is the concentration of the molecule that scattered the radiation. The typical value
for Raman scattering cross-section of molecules is between 10-31 and 10-26 cm-2 molecule1 [4]

.

A direct consequence of this low cross-section is one of the main limitations of Raman

spectroscopy: low signal intensity.
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2.1.1

Instrumentation for Raman Spectroscopy

Modern instruments for Raman spectroscopy generally consist of an optical microscope,
an excitation laser, light filters, and a sensitive detector (Figure 2-2). Light from a laser
beam, usually in the green (e.g., 532 nm), red (e.g., 633 nm), or near-infrared (e.g., 785
nm) regions, is passed through an interference filter to maintain a near-zero absorption
coefficient for the desired wavelength. Samples are then illuminated with the laser beam
focused through an optical microscope objective. High magnification and high numerical
aperture (N.A.) objectives provide higher spatial resolution than lower magnification and
lower N.A. objectives, which are beneficial when probing biological samples since specific
biological architecture can be examined.[7] Wavelengths that are close to the laser
wavelength, due to Rayleigh scattering, must be optically filtered out since Rayleigh
scattering is much more intense compared to Raman scattering.[8] Commonly used filters
include edge filters, which transmit light above or below the laser wavelength, and notch
filters, which allow both Stokes and anti-Stokes measurements by filtering out only the
excitation laser wavelength. The remaining unfiltered light is then passed through a
confocal pinhole, which allows only Raman scattering through from the focal plane of the
microscope, and is dispersed by a diffraction grating onto a detector and recorded. Since
Raman scattering intensity is very weak, detectors used in Raman systems must be very
sensitive. CCDs are most commonly used for their high quantum efficiencies and low
signal-to-noise ratios, especially in comparison to other detectors such as photomultiplier
tubes and photodiode arrays.[9] CCDs are made up of arrays of pixels that can each collect
charge from scattered photons, which is directly proportional to the Raman scattering
intensity. The resulting spectrum obtained is a plot of Raman scattering intensity versus
Raman shift in wavenumbers (cm-1).
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Figure 2-2: Schematic illustration of a general Raman spectrophotometer setup,
where the green beams and arrows represent the incident photons and the red beams
and arrows represent the Raman-scattered photons.

2.1.2

Raman Spectroscopy and Biological Samples

Although Raman spectroscopy is hailed for its molecular specificity, Raman analysis of
biological samples can be quite complicated since all biological systems are composed of
biological macromolecules such as lipids, proteins, nucleic acids, and carbohydrates.[10]
Vibrations of all modes from these macromolecules will be present in the spectra, and often
bands from different origins overlap, confounding the spectra and challenging spectral
analysis (Figure 2-3). However, there is a wealth of information available to researchers
on the classification of Raman spectra of biological systems, and with informed judgement
on the researcher’s behalf, peak assignments can be made.
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Figure 2-3: Raman spectral regions associated with proteins, nucleic acids, lipids, and
carbohydrates.
Proteins serve many biological functions in cells, including transmitted information and
controlling the passage of molecules around the cell membrane. As discussed in Chapter
1, proteins play important roles in EV formation and biogenesis. Raman spectroscopy is an
excellent technique to probe the protein structure of biological samples, whose signals are
found in the fingerprint region. Frequencies associated with protein backbones can be
found at 1230 – 1300 cm-1 (amide III),[11,12] 1550 cm-1 (amide II),[13] and 1630 – 1680 cm1

(amide I).[14-18] These ranges encompass α-helices (1270 – 1300 cm-1 and 1650 – 1655

cm-1),[11,18] β-sheets (1230 – 1240 cm-1,[12] 1630 – 1635 cm-1,[14,17] and 1660 – 1670 cm1 [15]

),

β-turns (1670 – 1680 cm-1),[16] and random coils (1240 – 1250 cm-1 and 1670 – 1680

cm-1).[12] Peaks corresponding to disulfides can be located around 505 – 550 cm-1, which
includes the gauche-gauche-gauche conformation at 505 – 515 cm-1, the gauche-gauchetrans and gauche-trans-gauche conformations at 520 – 530 cm-1, and the trans-gauchetrans conformation at 540 – 545 cm-1.[19,20] Lastly, common amino acid side chain peaks
can be found at 643 cm-1, 830 cm-1, and 1615 cm-1 (tyrosine),[21] 750 cm-1, 1010 cm-1, and
1550 cm-1 (tryptophan),[22] and 1003 cm-1, 1205 cm-1, and 1609 cm-1 (phenylalanine).[23]
Also found in the fingerprint region are nucleic acids. Many thorough studies have been
conducted to elucidate peaks for various nucleic acid moieties including sugars,
phosphates, and bases, which provide insight into backbone conformation and base pairing.
Regarding the bases, frequencies associated with ring breathing modes can be found at 668
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cm-1 (guanine), 668 cm-1, 746 cm-1, and 785 cm-1 (thymine), 726 cm-1 (adenine), 781 cm-1
and 785 cm-1 (cytosine), and 785 cm-1 (uracil).[24] Frequencies of unspecified ring modes
can be found at 1257 cm-1 (cytosine and thymine)[24] and 1336 cm-1 (adenine and
guanine),[25] while frequencies of ring stretching modes can be found at 1485 cm-1 (guanine
and adenine) and 1576 cm-1 (adenine and guanine).[25] Peaks corresponding to the backbone
of A-DNA are located at 807 cm-1 (O-P-O stretching), 1099 cm-1 (PO2- symmetric
stretching), and 1415 cm-1 (CH2 deformation), while peaks corresponding to the backbone
of B-DNA are located at 784 cm-1 (O-P-O symmetric stretching), 830 cm-1 (O-P-O
asymmetric stretching), 1090 cm-1 (PO2- symmetric stretching), and 1420 cm-1 (CH2
deformation).[26] Lastly, peaks belonging to the backbone of Z-DNA are found at 748 cm1

(O-P-O symmetric stretching), 748 cm-1 and 792 cm-1 (O-P-O asymmetric stretching),

810 cm-1 (O-P-O asymmetric stretching), 1095 cm-1 (PO2- symmetric stretching), and 1425
cm-1 (CH2 deformation).[26]
Spectral peaks of lipids and carbohydrates are generally found in the high frequency region,
although they can also be present in the fingerprint region. Raman spectroscopy can be
used to estimate certain structural properties of lipids such as the degree of unsaturation.
Spectral regions associated with lipids are as follows: 2800 – 3100 cm-1 (CH/CH2/CH3
stretching), 1600 – 1800 cm-1 (C=C and C=O stretching), 1400 – 1500 cm-1 (CH2/CH3
bending and scissoring), 1200 – 1300 cm-1 (CH deformation and CH2 twisting), 1050 –
1200 cm-1 (C-C and P-O stretching), 800 – 1050 cm-1 (CH bending, a skeletal C-O-O mode,
and N+(CH3)3 asymmetric stretching), and 500 – 700 cm-1 (CH2 bending, N+(CH3)3
symmetric stretching, C=O-O deformation, and cholesterol ring deformation).[27] Specific
lipid bands that have been identified include 1430 cm-1 (CH2 scissoring), 1443 cm-1
(CH2/CH3 deformation of lipids and triglycerides), and 1453 cm-1 (C-H bending),[28] as
well as 1749 cm-1 (C=O).[27] Bands at 2846 cm-1 and 3015 cm-1 have been used to quantify
total fatty acid content and total unsaturated fatty acid content, respectively.[29] Structural
investigations on different types of carbohydrates are very difficult since the basic
monomeric unit in polymeric carbohydrate chains is very similar. However, broad spectral
regions have been identified as follows: 3100 – 3600 cm-1 (O-H stretching), 2800 – 3100
cm-1 (CH/CH2 stretching), 1200 – 1500 cm-1 (CH/CH2 deformation), 800 – 1200 cm-1 (CO and C-C stretching), and 100 – 800 cm-1 (CCO deformation).[30]
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As mentioned in Section 2.1, the biggest disadvantage of Raman spectroscopy is the low
signal intensity caused by small Raman scattering cross-sections associated with molecules
(approximately 10-31 – 10-26 cm-2 molecule-1).[4] Raman spectroscopy of biological
molecules can be further complicated by the fact that many biological compounds are
fluorescent in nature. The fluorescence scattering cross-section is typically much larger
compared to the Raman scattering cross-section (approximately 10-16 cm-2 molecule-1) and
a resulting fluorescence background may suppress any underlying Raman spectrum to the
point where it is no longer detectable.[4,7] Fortunately, many techniques have emerged over
the past few decades that are capable of enhancing this weak Raman signal, one of which
is SERS.

2.2 Principles of SERS
As the name implies, SERS provides the same chemical information as conventional
Raman spectroscopy but with a dramatically enhanced signal (i.e., up to 1010
enhancement).[31] Additionally, minimal sample preparation is generally required, and
measurements can easily be multiplexed.[32] Since SERS is a surface-sensitive and nondestructive technique capable of single molecule detection,[33] it is a promising technique
for the characterization of EVs.[34,35]
SERS was first observed in 1974 by Fleischmann et al. when an unexpectedly large Raman
signal arose from pyridine adsorbed onto a roughened silver electrode.[36] Not long after
this observation, Albrecht and Creighton hypothesized that the phenomenon was due to the
formation of a molecule-metal complex.[37] Concurrently, Jeanmaire and van Duyne
hypothesized that the observed phenomenon arose from strong electrochemical fields at
the surface of the metal.[38] Not long after, Moskovits proposed the idea that the collective
oscillation of conduction electrons at the nanoscale roughness features on a metal surface
was responsible for the intense signal.[39,40] Studies since have confirmed that the SERS
enhancement arises from two distinct mechanisms based on initial hypothesis by Albrecht
and Creighton as well as Jeanmaire and van Duyne: the chemical enhancement mechanism
and the electromagnetic (EM) enhancement mechanism.[41,42]
The enhancement factor 𝐸𝐹 of a substrate can be determined experimentally by:[43]
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𝐸𝐹 = 𝐼

𝐼𝑆𝐸𝑅𝑆
𝑅𝑎𝑚𝑎𝑛

∙

𝑛𝑅𝑎𝑚𝑎𝑛
𝑛𝑆𝐸𝑅𝑆

(2-2)

In Equation 2-2, 𝐼𝑆𝐸𝑅𝑆 and 𝐼𝑅𝑎𝑚𝑎𝑛 represent the observed intensities with and without a
SERS substrate, respectively, of a specific vibrational mode, while 𝑛𝑆𝐸𝑅𝑆 and 𝑛𝑅𝑎𝑚𝑎𝑛
represent the number of molecules contributing to SERS and normal Raman scattering,
respectively. This equation is generally used to estimate the enhancement factor of a
substrate when both enhancement mechanisms are present. The main difficulty of
accurately estimating 𝐸𝐹 is properly defining the number of molecules in a given focal
volume that yield a Raman spectrum and a SERS spectrum.

2.2.1

Chemical Enhancement

The chemical enhancement mechanism arises from the physio-chemical interactions
between a substrate and analyte. For chemical enhancement to be observed, the analyte
must either be adsorbed during onto the substrate surface, or a very small (i.e., a few
Ångströms) distance away from the substrate.[32,44] Therefore, it is considered to be a shortrange effect. This mechanism is site-specific, analyte-dependent, and dependent also on
the orientation of the adsorbed analytes.[45]
The adsorption of a molecule on a substrate can be physical in nature (“physisorption”) or
chemical in nature (“chemisorption”). The former is driven by Van der Waals forces, and
so the interaction enthalpy is generally around -20 kJ mol-1.[46] As a result, the structure of
the molecule is modified only slightly. In the latter, a chemical bond is formed between the
molecule and the surface, and so stronger perturbation is expected. The interaction enthalpy
in this process is around -200 kJ mol-1.[46] In both physisorption and chemisorption
processes, the molecule’s electronic and geometric structure is changed, albeit to a different
extent. Therefore, the Raman cross-sections of its vibrational modes will generally be
different with respect to the free molecule, and the chemical enhancement factor 𝐸𝐹𝑐ℎ𝑒𝑚
can thus be defined as:[32]
𝐸𝐹𝑐ℎ𝑒𝑚 =

𝜎𝑘𝑎𝑑𝑠
𝑓𝑟𝑒𝑒

𝜎𝑘

(2-3)
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𝑓𝑟𝑒𝑒

In Equation 2-3, 𝜎𝑘𝑎𝑑𝑠 and 𝜎𝑘

refer to the Raman scattering cross-sections of the 𝑘-th

vibrational mode of the adsorbed and free molecule, respectively.
Chemical enhancement can arise from two different mechanisms, including the nonresonant chemical effect and the resonant charge transfer effect.[47] In the non-resonant
mechanism, the molecular orbitals of the analyte do not lay close enough in energy to the
Fermi level of the metal, and thus a new electronic state is not formed. This interaction,
however, may induce a geometrical change in the molecule as well as a change in the
electronic structure of the molecule, leading to a small change in the Raman shifts and
intensity of the vibrational modes.[32] Alternatively, chemical enhancement can arise from
the resonant charge transfer effect, which increases the probability of a Raman transition
by providing a pathway for resonant excitation.[44] If Raman scattering is excited with a
laser that is in resonance or pre-resonance with the metal-molecule charge transfer state,
Raman modes may be strongly enhanced, especially those coupled to the allowed
electronic transitions.[32] The resonant charge transfer effect can also be transient in nature,
in which temporary electron or hole transfer occurs between the metal and the analyte.[41]
Out of the two accepted theories for SERS enhancement, chemical enhancement is
generally thought to contribute less to the overall enhancement observed compared to
electromagnetic enhancement. The approximate contributions of the chemical
enhancement mechanism typically range from magnitudes of 102 – 104, where 102
enhancement is achieved from atomic scale roughness and 104 enhancement is achieved
through charge transfer resonance.[48]

2.2.2

EM Enhancement

The EM enhancement mechanism is based on the LSPR processes described in Section
1.3.3. Unlike the chemical enhancement mechanism, EM enhancement is analyteindependent but substrate-dependent. The LSPR of a given substate, which is the resonant
frequency of the conduction electrons at the metal surface, is governed by the size and
shape of nanoscale features on the metal substrate as well as the nature of the metal itself.[44]
When the frequency of impinging light matches the LSPR of the substrate, large EM fields
or “hot spots” are generated at the edges of the “roughness” features of the metal. When

43

analytes are confined within these large EM regions, the resulting Raman intensity is
greatly amplified.
The Raman scattering cross-section of a given molecule is dependent on the strength of the
local field |𝐸𝑙𝑜𝑐 |, and the enhanced local field acts on both incident and scattered rays of
light. Therefore, the overall Raman scattering cross-section is enhanced by the
enhancement factor 𝐸𝐹𝐸𝑀 which can be described as:[49]
𝐸𝐹𝐸𝑀 =

|𝐸𝑙𝑜𝑐 (𝜔𝐼 )|2
|𝐸0 |2

∙

|𝐸𝑙𝑜𝑐 (𝜔𝑅 )|2
|𝐸0 |2

(2-4)

In Equation 2-4, 𝐸𝑙𝑜𝑐 is the local field, 𝜔𝐼 is the frequency of the incident light, 𝜔𝑅 is the
frequency of Raman-scattered light, and 𝐸0 is the electric field of the incident light. In the
case of small Raman shifts, where 𝜔𝐼 ≅ 𝜔𝑅 , Equation 2-2 can be simplified to:[50]
𝐸𝐹𝐸𝑀 =

|𝐸𝑙𝑜𝑐 (𝜔𝐼 )|4
|𝐸0 |4

(2-5)

Equation 2-5 is known as the |𝐸|4 approximation. Consequently, a modest field
enhancement by a factor of 10 will yield an 𝐸𝐹 of 104. It is important to note that this
approximation is more accurate at small Raman shifts if 𝐸𝑙𝑜𝑐 (𝜔𝐼 ) is not too sharp near
𝜔𝐼 ,[32] and that some situations require a more specific approach for quantifying
enhancement. Nevertheless, the scaling of the enhancement factor to the fourth power
greatly increases the sensitivity of SERS for molecules that are located near or at hot spot
areas, allowing for even single molecule detection to be achieved.
The SERS effect arising from EM enhancement is generally strongest when the analyte is
confined within 1 – 10 nm from the roughness features, a sensing distance much farther
than what is required for chemical enhancement to be observed.[32] Therefore, the EM
enhancement mechanism can be thought of as the long-range effect. As mentioned above,
the EM enhancement mechanism is the dominant mechanism that contributes to the SERS
effect, which can reach magnitudes of 108 – 1010, where 108 enhancement is observed when
averaged over the substrate, and 1010 enhancement is observed in a hot spot area.[51]
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2.2.3

Materials for SERS

SERS substrates are traditionally fabricated with metals whose resonance positions are
located in the visible and near-infrared regions, thereby matching the wavelengths of
commonly used laser excitation sources (i.e., 532 nm, 633 nm, and 785 nm). Examples of
commonly used metals for SERS probes and substrates include gold, silver, copper, and
aluminum.[44] Gold and silver are the most commonly used metals for SERS
applications,[52,53] particularly in biological studies, with their own unique advantages over
the other. For example, gold has low toxicity and is far more stable in air than silver, which
tends to readily oxidize and react with sulfur compounds in the atmosphere.[54,55] Copper
and aluminum are less chemically stable in the environment as well, as they also form
oxide layers in air.[56,57] Oxidation of SERS substrates and probes can decrease their
plasmonic performances; for example, an oxide layer limits the proximity of an analyte to
the SERS-active metal surface, lowering the enhancement observed, and can modify the
analyte’s affinity towards the metal surface. However, silver, copper, and aluminum
substrates are much less expensive than gold substrates, which is not an insignificant factor
when considering a platform for various applications, such as point-of-care diagnostics.[58]
Less traditional materials for SERS substrates are dielectric[59] and semiconductor
materials,[60] which are being investigated to avoid optical losses[61] and unwanted
plasmonic heating[62] that can occur with metallic substrates. The absorption and
dissipation processes in metals leads to the release of heat which can modify an analyte.
For example, plasmonic heating has been observed to change the composition of protein
corona.[63] Non-metallic materials that have been studied in SERS substrates include
transparent conductive oxides (e.g., indium tin oxide, aluminum-doped zinc oxide, and
gallium-doped zinc oxide),[61,64] refractory transition metal nitrides (e.g., titanium nitride
and zirconium nitride),[65,66] and two-dimensional materials (e.g., graphene).[67,68] Although
interesting alternatives to conventional metallic probes and substrates, these materials have
not been widely adopted in the SERS characterization and analysis of EVs.
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2.3 Spectral Interpretation
Like Raman spectroscopy, a disadvantage of using SERS to probe complex biological
systems and samples such as EVs is that, unlike a small molecule, there is no single unique
spectral fingerprint or spectrum that can belong to a single EV. Unlike the standard
biochemical detection methods introduced in Section 1.3.2, which can identify specific
protein and lipid cargo of EVs, SERS can only be used to identify small molecular moieties
not necessarily specific to a particular biological macromolecule. Therefore, SERS spectra
are generally interpreted by reducing their dimensionality, determining peaks responsible
for the most variance within a data set, and establishing patterns for a set of EVs. Such
methods include the commonly used PCA,[69,70] which can be used on its own or in series
with stronger classification methods such as linear discriminant analysis (LDA)[71,72] or
machine learning.[73,74]

2.3.1

Principles of PCA

PCA is a method for dimensionality-reduction that involves transforming a large set of
variables into a smaller one that contains most of the information of the original data set.[75]
The new variables produced by this method are referred to as principal components (PCs)
and are constructed as linear combinations of the initial variables.[76] PCs are uncorrelated
and most of the information of the initial data set is contained in the first PCs. For example,
a data set with 5 dimensions will be represented by 5 PCs, where the maximum variance
or information is squeezed into the first PC, then next, and so on until 100 % of variance
is explained (Figure 2-4A). PCA is extremely valuable for the analysis of spectral data
since these data sets can have hundreds or thousands of dimensions (i.e., wavenumbers).
Before treating data with PCA, the data must be standardized so that each initial variable
contributes equally to the analysis.[77] PCA is sensitive to the variances in the initial data
set, and variables with larger ranges will dominate over those with smaller ranges, leading
to biased results. Covariance matrices are computed to identify correlations among the
input data set. The sign of the covariances indicate how the variables are correlated: if the
covariance is positive, then the two variables increase or decrease together (i.e., directly
correlated), but if the covariance is negative, then one variable increases while the other
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decreases (i.e., inversely correlated). Simply put, covariance matrices are tables that
summarize the correlations between all possible pairs of variables. PCs can be solved by
determining the eigenvectors and eigenvalues for the covariance matrices. For a data set
with 5 dimensions, there are 5 variables, and so 5 eigenvectors will be calculated with 5
eigenvalues. The eigenvectors of a covariance matrix are the directions of the axes where
there is the most variance (i.e., most information). In other words, the eigenvectors
corresponding to the covariance matrix are the PCs. Ranking the eigenvalues from highest
to lowest will rank the PCs in order of significance, and the graphical interpretation of this
is what is known as a scree plot (Figure 2-4B). The percentage of explained variance of
each PC is calculated by dividing the eigenvalue of each component by the sum of
eigenvalues. Recasting the data along the PC axes generates score plots (Figure 2-4C),
which can be useful in classification tasks and examining trends in the data.

Figure 2-4: Schematic illustration of the process of PCA. (A) The original 5-variable
data set can be visually represented by a maximum of 3 axes. The first PC is fitted so
that it contains the maximum variance, and the second is positioned perpendicular to
it. (B) The 5 calculated PCs can be visualized in a scree plot, and (C) a score plot is
created by re-casting the original data on PC1 and PC2 axes.
Naturally, simplifying a data set in this manner will lead to a decrease in accuracy.
However, reducing the complexity of a spectral data set makes it easier to visualize and
analyze the data, and also reduces the computational demand when further using machine
learning or deep learning algorithms. However, PCA alone often fails to distinguish classes
or separate them with a high enough accuracy to be used in diagnostic applications. This
is due to the fact that PCA is an unsupervised transformation technique, meaning it ignores
class labels. Usually, PCA is used in combination with techniques that explicitly attempt
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to model the difference between classes of data such as LDA. While PCA determines the
relationship between independent variables, the supervised technique LDA determines the
relationship between dependent and independent variables, resulting in class separation by
finding a lower-dimensional space that has better discriminatory power.[78] Another
method that can be used to achieve higher classification accuracy than PCA is machine
learning.

2.3.2

Machine Learning

Machine learning is a type of artificial intelligence that is based on the idea that systems,
with minimal intervention from humans, can learn from data, identify patterns in data, and
make decisions. Although machine learning has been around as early as the 1950s,[79]
recent developments made in the past couple of decades has led to its widespread use in
many applications, including, but not limited to, finance analysis,[80,81] fraud detection,[82,83]
search engines,[84,85] marketing,[86,87] and medical diagnosis.[88,89]
Two broad categories of machine learning are unsupervised machine learning, in which no
labels are provided to the system and the algorithm finds hidden patterns in a data set, and
supervised machine learning, whereby the system is trained through example inputs and
their desired outputs.[79] Some of the most common supervised machine learning
techniques include regression and forecasting, in which the machine analyzes trends in past
and present data to make predictions about the future, and classification, in which the
machine learns to draw conclusions from the data set and determines into which categories
new observations belong.
Supervised machine learning with the goal of finding a classifier generally consists of the
identification of a problem and required data, data pre-processing, selection of a training
set, selection of an algorithm, training, and evaluation with a test set (Figure 2-5).[90] The
researcher is, of course, responsible for the collection of data and its pre-processing to
reduce noise and outliers. In cases with large data sets, dimensionality reduction (e.g., by
PCA) is suggested to reduce computational time and improve computational efficiency.
The choice of learning algorithm is a critical step in the machine’s classification
performance and is assessed by computing prediction or classification accuracy. Classifier
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evaluation can be achieved by randomizing the data and splitting it into training and test
sets, the ratio of which is defined by the user (e.g., 80 % is used for training and 20 % is
used for testing).[91] Alternatively, classifiers can be evaluated by cross validation (CV), in
which the data set is split into 𝑛 mutually exclusive and equally sized subsets. In CV, 𝑛 −
1 subsets are used as training sets while the remaining set is used as a test group until each
subset has been used for testing once, and the error rate of each subset is averaged to
estimate the error rate of the classifier.[90] Leave-one-out CV (LOOCV) is a special case of
CV in which each piece of data is used to train and test the classifier, which is the most
accurate estimator of the classifier’s error rate, but the most computationally expensive.[90]
If the classification performance is unsatisfactory, modifications must be made, which can
look like fine-tuning training parameters, selecting a different algorithm, reducing data or
problem dimensionality, or even collecting a larger data set for training. The best learning
method for a set of data can be chosen from a variety of different algorithms, which can be
logic-based, perceptron-based, statistical, instance-based, or support-vector machines
(SVM).

Figure 2-5: Schematic illustration of the process of supervised machine learning.
A common example of a logic-based algorithm is the decision tree, which classifies
instances (i.e., rows of data) by sorting them based on features, or input variables, in a
sequence of branching statements (Figure 2-6A).[92] The first split, or root node, considers
all features of the training data during the test. Branches represent outcomes of tests, and
can either flow into internal nodes, which are tests on the attributes, or leaf nodes, which
hold class labels. Decision trees tend to perform better when features are discrete or
categorical rather than continuous.[90] While decision trees are easy to read and interpret,
they can create overly complex models that pose the risk of overfitting data.[93] While
decision trees can be translated into a set of rules by creating a separate rule for each branch,
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rules can also be directly induced from the training data via a rule-based algorithm,[94] such
as the CN2 algorithm.[95] Rule-based algorithms are typically more comprehensible
compared to decision trees when learning binary problems since rule-based algorithms
learn a set of rules for the positive class only. However, if multiple classes must be learned,
decision trees are more efficient than rule-based algorithms since they consider the entire
data set one class at a time.[90]
Perceptrons or “artificial neurons” are nodes in artificial neural networks (ANNs) that take
one or more input values, run a (typically nonlinear) function on the weighted sum of the
inputs, and compute a single output value.[96] Feed-forward ANNs allow signals to travel
in only one direction (i.e., input to output) (Figure 2-6B).[97] A hidden layer between the
input and output layers contains a function for training. The network is initially trained on
a set of paired data to determine input-output mapping, and weights of the connections
between neurons are fixed. When a new data set is introduced, the network is used to
determine new classifications. Multilayer perceptron-based ANNs can usually provide
incremental learning more easily compared to decision trees, but training time is usually
much longer and they perform about equally as well.[90]
Statistical learning algorithms, in contrast to neural networks, have an explicit underlying
probability model, meaning they calculate a probability that an instance belongs in each
class, rather than a simple classification.[90] Examples of statistical learning algorithms
include LDA, discriminant correspondence analysis (DCA), Bayesian networks, and
logistic regression. LDA, as mentioned in Section 2.3.1, finds the linear combination of
features which best separates classes.[98] LDA is used when observations are continuous
quantities, while DCA is an equivalent technique used for discrete or categorical data. [90]
Bayesian networks are graphical models for probability relationships among a set of
variables and, unlike decision trees or neural networks, can consider prior information
about a given problem in terms of structural relationships among its features (Figure 26C).[99] However, since Bayesian network classifiers try to construct a very large network,
it is not a suitable method for examining data sets with many features.[100] Logistic
regression is often used in binary classification problems and implements a sigmoid
function to convert the raw prediction of a linear model into a value between 0 and 1.[101]

50

This output value can be interpreted as either the probability that the instance belongs to
the positive class in the binary classification problem or as a value to be compared against
a classification threshold (i.e., a criterion separating positive and negative classes).
Instance-based learning algorithms are specific types of statistical methods. Since instancebased learning algorithms delay the generalization process until classification is performed,
they are known as lazy-learning algorithms.[102] Such algorithms require less computational
time during the training phase compared to eager learning methods (e.g., decision trees,
neural networks, and Bayesian networks), but require more computational time during
classification. One of the most common instance-based learning algorithms is k-Nearest
Neighbor (kNN), which is based on the idea that instances within a data set will generally
exist in close proximity to other instances that have similar qualities or properties (Figure
2-6D).[103] Using labelled instances, the value of the label of an unclassified instance can
be determined by observing the class of its nearest neighbors, and the algorithm locates its
k nearest instances and determines its class by identifying the single most frequent class
label. Although kNN can be very powerful, they can become very computationally
expensive since the only to choose k (i.e., number of nearest instances to consider) is
through cross validation.[90]
Compared to other machine learning algorithms, SVM has emerged quite recently. SVMs
are based on “margins” surrounding hyperplanes that separate data classes (Figure 26E).[104] Support vectors refer to the data points closest to the hyperplane that influence its
optimal position and orientation. By maximizing the margin, the largest possible distance
is created between the separating hyperplane and the instances on either side of it, which
increases the confidence in the projections and reduces the expected generalization error.
Since the number of support vectors selected by the SVM is usually small, the number of
features in a data set does not affect the model complexity of an SVM, making SVMs
suitable to deal with learning tasks in which the number of features is large compared to
the number of training instances.[90]
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Figure 2-6: Schematic illustrations of some machine-learning algorithms,
highlighting (A) decision trees, (B) feed-forward ANNs, (C) Bayesian networks, (D)
kNNs, and (E) SVMs.
The discriminatory power of classification models is commonly compared using accuracy,
sensitivity, specificity, and receiver operator characteristic (ROC) curves.[101] Sensitivity,
which can also be referred to as recall, is a measure of the true positive rate, while
specificity is a measure of the true negative rate. Plotting (1 – specificity) versus sensitivity
at varying values of classification threshold generates an ROC curve, which is a simple
graphical tool for displaying the accuracy of a diagnostic test.[105] The area under the curve
(AUC) of the ROC curve is therefore a summary of the diagnostic accuracy. An AUC value
of 0.5 corresponds to random chance, while an AUC value of 1.0 corresponds to perfect
accuracy. While an AUC greater than 0.5 is generally good, researchers aim for as close to
1.0 as possible, which is especially important in medical applications. If the AUC is less
than 0.5, the test is worse than random chance.[106]
There is no single learning algorithm that can uniformly outperform other algorithms
across all data sets. The simplest approach to determine the most accurate algorithm for a
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particular data set is to estimate the accuracies of several algorithms and select the
algorithm that is most accurate. In Chapters 3 and 4, several algorithms are tested and
compared to determine the best algorithms for classifying MSC-derived EVs and cancerderived EVs.

2.4 SERS Probes and Platforms for EV Capture and
Characterization
SERS probes and platforms can generally be grouped into two methods: direct or “labelfree” detection and indirect detection. Direct detection methods allow for direct probing of
an analyte without a label or “tag”, since the analyte’s SERS spectrum is recorded. [107,108]
Indirect detection methods rely on a SERS tag for analyte detection. SERS tags consist of
an efficient Raman reporter, which is a molecule with a large Raman-scattering crosssection and characteristic peak or spectrum, and are engineered to selectively bind to the
analyte. The analyte is thus detected through the Raman reporter, whose signal intensity is
proportional to the analyte concentration.[109,110] Indirect detection can be used when
analytes are immersed in complex matrices (e.g., plasma) that can generate an interfering
signal with the analyte. Although indirect detection often requires more complex
fabrication and analysis compared to direct detection, the available sensitivity and
specificity are oftentimes much higher. The main disadvantage of indirect detection is that,
although readout is greatly simplified for medical personnel who are not experts in Raman
spectroscopy, rich biological information is lost when true analyte signals are not tracked.
SERS probes and platforms have been developed for EV analysis using both direct
detection and indirect detection methods; the former is reviewed in Sections 2.4.1 and 2.4.2
while the latter is reviewed in Sections 2.4.3 and 2.4.4. Although both are reviewed to
discuss recent advances and shortcomings of current studies, only direct SERS sensing is
used in Chapters 3 and 4.

2.4.1

Nanoparticle Probes for Direct Sensing

Nanoparticle probes, either cast on a substrate or in suspension, are commonly used for
SERS due to their simplicity. Simple gold nanoparticles (AuNPs) have been used as SERS
probes in the characterization of EVs derived from lung cancer cells.[111-113] AuNPs with a
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diameter of approximately 80 nm were implemented by Park et al. to probe EVs analyzed
from two lung cancer cell lines, H1299 and H522, as well as from alveolar cells as a normal
control.[111] These AuNPs were dried on coverglasses, and SERS measurements were
performed on dried EVs overtop the substrate with an excitation wavelength of 785 nm.
Using PCA, cancerous EVs and normal EVs could be discriminated with 95.3 % sensitivity
and 97.3 % specificity, although accuracy was not reported. The authors further attempted
to use PCA score plots to predict the outcomes of clinical samples consisting of 2 lung
cancer patients and 2 healthy individuals. However, the platform failed at this stage, as the
clinical sample scores did not fall into the 95 % confidence ellipses of their respective
group. One year later, Shin et al. built on this work, instead clustering AuNPs on a (3aminopropyl)triethoxysilane (APTES)-coated substrate.[112] In contrast to the previous
work, the authors instead performed SERS measurements in a liquid state to prevent signal
deformation by EV damage or salt formation. The AuNPs were also coated with
cysteamine, which has been used to induce the electrostatic adsorption of EVs via
interactions between the cationic amino groups of cysteamine and anionic EV surfaces.
Cancer cell lines PC9 and H1299 were investigated with the normal lung cell line HPAEC
as a control. Although cancerous and noncancerous groups could be distinguished by PCA,
the authors did not report sensitivity or specificity for comparison with the previous study.
Additionally, despite the proposed SERS effect, the raw spectra still contained background
fluorescence, thus requiring treatment prior to analysis.
Recently, Shin et al. implemented the same substrate idea, but greatly improved analysis
with a sophisticated deep learning algorithm.[113] AuNPs with 100 nm diameter were coated
onto an APTES-covered substrate (Figure 2-7A), and used to analyze dried EVs from lung
cancer cell lines (A549, H460, H1299, H1763, and PC9) and from normal alveolar
epithelial cells HPAEC (Figure 2-7B). The deep learning algorithm trained with 80 % of
the cell-derived EV data could predict the validation set with 94.8 % accuracy, and thus
the entire cell-derived data set was used as a training set to predict the outcomes of clinical
plasma-derived EVs (Figure 2-7C). The clinical data set was comprised of 20 healthy
individuals and 43 lung adenocarcinoma patients. The lung cancer patients were further
identified by their disease stage, where 22 patients had stage IA cancer, 16 patients had
stage IB cancer, and 5 patients had stage II cancer. PCA was employed to determine the
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similarity between the clinical samples and the cancer cell line-derived EVs, which was
quantified by calculating the Mahalonobis distances between PC score clusters (Figure 27D). On average, cancer patients displayed 1.5 times more similarity to the cancer cellderived EVs compared to the healthy individuals, and the cancer patients could be
discriminated from the healthy individuals with 84 % sensitivity and 85 % specificity.
Furthermore, the authors established the potential of the device for early cancer screening
by discriminating the stage IA patients from the healthy individuals with 73 % sensitivity
and 85 % specificity. However, like the previous study, the raw spectra required significant
preprocessing prior to analysis due to high background fluorescence, and the calculated
sensitivity and specificity remains low for clinical translation.

Figure 2-7: A 100 nm AuNP-covered SERS substrate for the analysis of lung cancerderived EVs. (A) SEM images and an optical image (inset, top left) of the AuNPs
assembled over an APTES-covered substrate. (B) Schematic illustration of the
acquisition of SERS spectra. (C) Lung cancer cell line-derived EVs and normal lung
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cell line-derived EVs are used to train a deep learning algorithm for lung cancer
diagnosis. (D) The deep learning model is tested with EVs derived from lung cancer
patients and healthy individuals, and their similarities to the lung cancer cell-derived
EVs are compared. Adapted with permission from reference [113] (copyright 2020
American Chemical Society).
Simple nanoparticles have additionally been used as SERS probes to characterize EVs
derived from pancreatic and cervical cancer cells.[114,115] AuNPs with 10 nm diameter were
utilized by Carmichael et al. to analyze EVs from two pancreatic cancer cell lines,
CD18/HPAF and MiaPaCa, and a normal pancreatic cell line, HPDE, and SERS
measurements were performed with a 785 nm excitation wavelength.[114] With principal
component analysis-discriminant function analysis (PCA-DFA), cancer EVs could be
discriminated from normal EVs with 90.0 % accuracy, 90.6 % sensitivity, and 97.1 %
specificity. The probes were further tested with clinical samples from patient sera,
examining 10 healthy individuals and 10 early-stage pancreatic cancer patients. However,
the discriminatory capabilities were not as strong as with the cell line models, with
characterization efficiencies ranging from 20 – 87 % for healthy individuals and 30 – 90
% for cancer patients. Another research group utilized citrate-reduced silver nanoparticles
(AgNPs) with 200 nm diameter to analyze cervical cancer EVs.[115] Such nanoparticles
were able to surround individual EVs (approximately 2 – 5 AgNPs per vesicle), and
displayed a resonance position around 434 nm. Spectra of EVs from two cervical cancer
cell lines, HeLa and Atg5-/-, and one noncancerous cell line, HEK293, were collected with
a 633 nm excitation wavelength and analyzed by PCA. Although the cluster of normal EVs
was separate from the HeLa-derived EVs, the normal EVs overlapped with the Atg5-/-derived EVs, and accuracy, sensitivity, and specificity were not reported. Furthermore,
each spectrum was heavily dominated by background peaks resulting from the total
exosome isolation reagent used for EV isolation.
Recognizing the importance of single vesicle characterization for diagnostic applications,
Stremersch et al. implemented 4-(dimethylamino)pyridine (DMAP)-coated AuNPs
approximately 10 nm in diameter.[116] DMAP-coated AuNPs were able to form irregularlyshaped nanoshells around single EVs based on the electrostatic absorption of cationic
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DMAP-AuNPs onto anionic EV surfaces, and display an LSPR band around 522 nm. The
authors analyzed EVs derived from melanoma cell line B16F16 and red blood cell (RBC)derived vesicles, and SERS spectra were obtained with a 785 nm excitation wavelength.
Using partial least squares-discriminant analysis (PLS-DA), melanoma EVs could be
discriminated from RBC-derived EVs with 88.0 % sensitivity and 95.4 % specificity, while
accuracy was not reported. Although the authors attempted to characterize both spectra,
EV-related peaks were generally poorly resolved, and each spectrum was additionally
dominated by presumed DMAP molecules. In addition to having a high Raman scattering
cross-section, DMAP molecules are closest to the AuNP surface, and therefore at the region
of highest enhancement. To address the problem of DMAP-dominated spectra, Fraire et al.
developed in situ silver-coated AuNPs.[117] In situ-coating of silver allowed the EV
membrane to be in direct contact with a metal surface (Figure 2-8A,B), as opposed to
DMAP, and also shifted the LSPR to 490 nm, with an additional band appearing at 418
nm. The same EV sources were analyzed again, and with PLS-DA, melanoma EVs could
be discriminated from RBC-derived EVs with 91.7 % sensitivity and 96.9 % specificity,
an improvement compared to the use of bare DMAP-coated AuNP probes (Figure 28C,D). Although DMAP peaks no longer dominated each spectrum, there remained
substantial noise in both spectra, and both studies may have benefited from using a laser
excitation wavelength better matched to the LSPR of the probes, such as a 532 nm laser.
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Figure 2-8: DMAP-coated AuNPs with silver nanoshells are used as SERS probes for
the analysis of melanoma-derived EVs. Schematic illustrations of SERS acquisition
(A) without and (B) with the silver nanoshell, highlighting the closer proximity of the
EV membrane to the SERS-active metal surface when the probes are coated in situ
with a silver layer. Analysis of melanoma cell line-derived EVs (red cluster) and RBCderived EVs (green cluster) (C) without and (D) with the silver nanoshell, illustrating
higher discriminatory power when the silver nanoshell is implemented. Adapted with
permission from reference [117] (copyright 2019 American Chemical Society).
Magnetic beads (MBs) functionalized for EV capture are commonly used in the SERS
analysis of EVs. With the application of an external magnet, EVs can be concentrated under
a laser spot, further enriching signal intensity.[118-121] Li et al. have reported gold nanodotcovered MBs for the analysis of breast cancer EVs.[118] Superparamagnetic nanoparticles
were modified to introduce thiol groups for the anchorage of gold nanodots and were
further functionalized with anti-CD9 for EV capture. Such probes had a diameter of 360
nm and displayed an LSPR band around 540 nm. EVs from two breast cancer cell lines,
MCF-7 and MDA-MB-231, were chosen due to the cell lines’ differences in metastatic
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potential. With PCA, the two groups were able to be discriminated with 100 % sensitivity
and specificity. The authors further tested the platform with clinical serum samples from
14 breast cancer patients and 6 healthy individuals, and were able to discriminate these
groups with 91.67 % sensitivity and 100 % specificity. Although the calculated sensitivities
and specificities appear extremely high, it is important to note that a very limited sample
size was used, and the reported SERS spectra across the groups were virtually identical.
The spectra appear not to have been standardized prior to PCA, in which case the PC score
plots are based on variations in signal intensity rather than variations in Raman shift.
Variations in Raman signal intensity cannot be interpreted without knowing analyte
concentrations.
An unconventional substrate consisting of AgNPs grown in situ into bacterial cellulose
(BC) from commercial nata de coco was described by Ferreira et al.[122] The motivation
behind this work was to develop a cost-efficient SERS substrate for breast cancer
diagnosis, since silver is less expensive than the more commonly used gold, and nata de
coco is a low-cost and mass-produced source of BC. The AgNPs grown into the BC
membrane were approximately 92 nm in diameter, providing an LSPR band around 390 –
460 nm. EVs were analyzed from the breast cancer cell line MDA-MB-231, with
nontumorous breast epithelial cells MCF-10A used as a control. A laser with an excitation
wavelength of 532 nm was used to probe 20 cancerous and 18 normal samples, and PCA
was used to discriminate the groups. No overlap was observed between the 95 %
confidence ellipses of the two groups. Furthermore, 2 test samples (i.e., 1 cancer-derived
sample and 1 normal sample) were used as proof-of-concept to demonstrate diagnostic
potential, and each fell into their respective cluster. However, limited sample sets were
used in this study.
Another novel nanoparticle-based substrate was proposed by Pramanik et al., who
implemented a mixed-dimensional heterostructure platform consisting of two-dimensional
graphene oxide and gold nanostars (GO-AuNS) for the analysis of breast cancer EVs.[123]
The SERS effect is influenced by both the GO and the AuNSs, the former of which
contributes via the chemical enhancement mechanism, whereas the latter contributes via
the stronger electromagnetic enhancement mechanism. A strong LSPR band around 580
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nm is observed, as well as a broader band around 720 nm, and so the authors selected a 670
nm excitation laser. EVs from breast cancer cell lines MDA-MB-231 and SKBR3 were
characterized by SERS. Although the spectra were well-characterized, a normal control
group was not utilized, and so conclusions cannot be drawn to the platform’s diagnostic
potential.

2.4.2

Periodic Arrays of Nanostructures for Direct Sensing

Nanopillars are common, simple SERS substrates for EV analysis.[124-126] Early work
involving pillars for SERS analysis of EVs was published by Tirinato et al., who fabricated
super hydrophobic structures (silicon micropillars, approximately 10 nm in diameter) by
standard optical lithography techniques and reactive ion etching (RIE).[124] The pillars were
further covered with silver nanoaggregates. EVs from a colon cancer cell line (HCT116)
and from healthy colon cells (CCD-841-CoN) were analyzed by SERS with a 514 nm
excitation wavelength. However, the SERS spectra of both EV types appeared nearly
identical, with variations limited to differences in intensity rather than peak positions. In
addition to limited characterization, the diagnostic potential of the platform was not
assessed. Many years later, Sivashanmugan et al. proposed a gold nanorod (AuNR) array
covered with silver nanocubes (AgNCs) on top of the rods for the analysis of lung cancer
EVs.[125] AuNRs, with diameters of approximately 126 nm and heights of approximately
400 nm, were fabricated by a focused ion beam method. AgNCs with edge lengths of
approximately 65 nm were able to self-assemble overtop the pillars. The resulting gap
mode substrate provided three LSPR modes around 529 nm, 752 nm, and 881 nm. EVs
from three lung cancer cell lines (HCC827, H1975, and PC9) and three normal lung cell
lines (L929, BEAS-20, and NL-20) were analyzed by SERS with a selected excitation
wavelength of 785 nm. The normal EVs exhibited strong protein, nucleic acid, and lipid
signals, while the cancer-derived EVs exhibited only strong protein signals. Additionally,
the authors found that the cancer-derived EVs displayed a higher diversity in peaks
compared to the normal EVs, which was confirmed by Western blotting, and potentially
the result of the highly dysregulated feature of cancer cells. Although the authors describe
the potential of this platform in diagnostic applications, diagnostic criteria such as
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accuracy, sensitivity, and specificity were not assessed. Furthermore, the SERS spectra of
all six EV types were extremely noisy, with peaks not well-resolved.
A novel nanopillar array was proposed by Kim et al. and named Functionalized Array for
SERS (FASERS).[126] Gold nanopillars with 300 nm diameter and 500 nm height were
fabricated by colloidal lithography and plasma etching and were functionalized with 8
different self-assembled monolayers (SAMs) (Figure 2-9A,B). The SAMs varied in
functional group (i.e., alkyl, hydroxyl, carboxyl, and amine) as well as in carbon chain
length (i.e., 3-carbon and 11-carbon). SAMs were selected for EV capture as an alternative
to an immunoaffinity-based approach, so that compositional diversity of biological
samples are not lost. When examined with small test molecules, the SERS signal was
observed to substantially diminish with longer-chain SAMs, owing to the fact that the
molecule is positioned farther away from the enhancement region of the nanopillars.
Carboxyl and amine groups were also generally able to provide more favorable interactions
with test molecules, leading to a higher observed SERS signal compared to the other
SAMs. The platform was tested with EVs from the breast cancer cell line MDA-MB-231
using an excitation wavelength of 785 nm (Figure 2-9C). However, since EV analysis was
not the focus of the paper and rather for proof-of-concept, multivariate analysis was not
reported. Instead, the authors tested the platforms with more complex cell lysates from the
breast cancer cell line Hs578T and from the normal cell line Hs578Bst. With PCA-LDA,
the lowest obtained accuracy was 41.7 %, obtained with the 11 carbon-length COOH SAM.
The highest accuracy obtained was with the 3 carbon-length NH2 SAM at 91.7 %, with a
corresponding sensitivity and specificity of 83.3 % and 100 %, respectively. Although an
interesting platform design, the diagnostic potential is not as high as other SERS platforms
that use EVs for analysis.
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Figure 2-9: FASERS substrate for the analysis of breast cancer-derived EVs and cell
lysates. (A) Schematic illustration of FASERS. Each SAM uniquely provides insight
into the biological composition of a given analyte. (B) Schematic illustration (top),
top-view SEM image (bottom left), and tilted-view SEM image (bottom right) of the
bare FASERS (scale bars = 400 nm). (C) SERS spectra of breast cancer cell linederived EVs collected with each FASERS. Adapted with permission from reference
[126] (copyright 2020 Yarovsky, I. & Stevens M. M.).
A periodic array of gold pyramidal nanostructures overlaid with single-layer graphene for
the analysis of lung cancer-derived EVs was reported by Yan et al.[127] Such nanopyramids
have a base edge length of approximately 200 nm and 57.7 ° sidewall angle, as well as a
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center-to-center distance of approximately 400 nm. The graphene layer serves a dual
purpose: to provide a biocompatible and protective layer over the metal surface (e.g.,
prevent oxidation) since it is chemically inert, and to gauge local EM field intensity.
Gauging the EM field intensity by normalizing the biological SERS signal with the
graphene peaks allows for the direct correlation of the biological analyte peaks with the
amount of analyte present in the sample, as opposed to a convolution existing between the
EM field intensity and the amount of analyte. EVs from two lung cancer cell lines, HCC827
and H1975, were analyzed by SERS with a 785 nm excitation wavelength, and human and
bovine serum were used as controls. Using PCA, all four sample sources could be separated
with < 5 % overlap among groups and a sensitivity > 84. %. Interestingly, the highest
degree of overlap was not between the two lung cancer cell groups, but between the H1975derived EVs and the bovine serum. However, the sensitivity achieved is not competitive
with other SERS substrates and methodologies for cancer diagnosis, and accuracy and
specificity were not assessed.
Recently, a microfluidic device based on silver nanobowtie-shaped antennae was reported
by Jalali et al.[128] These antennae were approximately 150 nm in length, with gaps ranging
from 0 – 100 nm, and provided three LSPR modes at 410 nm, 460 nm, and 580 nm. The
microfluidic device was fabricated by a top-down standard lithography method while a
bottom-up method based on the self-assembly of a polystyrene monolayer on silicon was
used to fabricate the antennae. EVs derived from two human glioma cell lines, U373 and
U87, were analyzed by SERS using an excitation wavelength of 532 nm, along with
synthetic liposomes and normal glial cells (NHA) as controls. Such groups could be
distinguished by PCA, as their 95 % confidence ellipses displayed low overlap.
Additionally, the U87-derived EVs could be discriminated from the U373-derived EVs,
the latter of which shared more similarity with the normal EVs. However, a limited sample
size was studied, and clinical samples have not yet been analyzed. Furthermore, the
antennae were not uniformly distributed over the substrate surface, meaning the EM field
intensity is not homogenous across the substrate. Since the authors utilized silicon for
substrate fabrication, a strong silicon peak around 520 cm-1 was present in the spectra, and
so the spectra required normalization.
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An unconventional, grooved SERS substrate for EV analysis was proposed by AvellaOliver et al.[129] These structured polycarbonate substrates were obtained from standard
recordable disks (CD-R and DVD-R) and coated with silver for SERS. The goal of this
study was to develop an extremely cost-effective device by reusing disks and by utilizing
silver instead of gold. The groove pitches for the DVD-based and CD-based substrates
were approximately 1.4 μm and 0.7 μm, respectively. The resulting LSPRs were located at
650 nm for the DVD-based substrates and at 780 nm for the CD-based substrates. EVs
from lung cancer cell line A549 were analyzed by SERS, with excitation wavelengths of
633 nm (for the DVD-based substrates) and 785 nm (CD-based substrates). Although the
SERS spectra were published, the authors did not characterize the spectral peaks. The paper
was positioned as proof-of-concept, focusing more on the novelty of the substrate rather
than the diagnostic potential, so normal controls were not analyzed as opposed to most
studies.
A novel beehive-inspired three-dimensional gold-coated TiO2 macroporous inverse opal
(MIO) structure was introduced by Dong et al. (Figure 2-10A).[130] Advantages of such a
substrate include ideal trapping conditions for separating EVs from biofluids (Figure 210B) and the enhancement of Raman signal by both LSPR and by the slow light effect (i.e.,
the ability to trap and scatter light multiple times). With a pore diameter of approximately
290 nm, the resulting resonance band was located around 630 nm. EVs from prostate
cancer cell line LNCaP and normal prostate cell line RWPE-1 were analyzed by SERS
using an excitation wavelength of 633 nm. Since protein phosphorylation is one of the most
fundamental mechanisms for the regulation and control of protein activities and functions
within cells, the authors monitored the degree of protein phosphorylation by quantifying
the spectral peak at 1087 cm-1, corresponding to the P-O bond. LNCaP-derived EVs
displayed a P-O peak approximately 3.0 times higher than RWPE-1-derived EVs,
indicating a higher degree of protein phosphorylation in the cancer cells. The authors also
analyzed EVs derived from patient samples, assessing not only prostate cancer patients,
but lung, liver, and colon cancer patients as well. EVs were derived from 15 prostate cancer
patients, 15 lung cancer patients, 15 liver cancer patients, 8 colon cancer patients, and 10
healthy individuals. Again, a higher degree of protein phosphorylation was observed in the
cancer-derived EVs, with the P-O peak 2 – 2.5 times more intense than that from the normal
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control group (Figure 2-10C) and was stronger in over 93 % of cancer cases compared to
the healthy individuals. However, the patient data sample size was limited, and the authors
did not report accuracy, sensitivity, and specificity based on their method.

Figure 2-10: A beehive-inspired three-dimensional gold-coated TiO2 MIO structure
for the analysis of prostate cancer, lung cancer, liver cancer, and colon cancer
derived-EVs. (A) Schematic illustration of the structure fabrication and acquisition
of SERS spectra. (B) SEM image of the substrate that has captured 4 EVs, which are
circled in red (scale bar = 300 nm). (C) The P-O band intensities of EVs derived from
cancer patients are significantly higher on average compared to the P-O band
intensities of EVs derived from healthy individuals. Adapted with permission from
reference [130] (copyright 2020 American Chemical Society).
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Other nanoarrays consisting of cavities for EV capture have been reported, such as silver
nanobowls fabricated by soft lithography[131] and nanoholes fabricated by electron-beam
lithography.[132,133] Since these platforms were used in the investigation of ovarian cancerderived cells in literature and for this thesis, respectively, they are reviewed in detail in
Chapter 4.

2.4.3

Probe-Based Immunocomplexes for Indirect Sensing

One sandwich-type immunocomplex detailed by Zong et al. consists of a magnetic capture
probe and a gold core-silver shell nanorod (Au@AgNR) as a SERS tag.[119] Prior to
functionalization with capture antibody anti-CD63, the Fe3O4 MBs are coated with a silica
shell to provide more available surface area for the antibodies as well as to protect the MBs
from degradation. The Au@AgNRs are attached to Raman reporter 5,5-dithiobis-(2nitrobenzoic acid) (DTNB) via Ag-S bonds and further coated with a silica shell to protect
the DTNB from disturbance from the outer environment. For binding with EVs, the DTNBtagged Au@AgNRs are further functionalized with rabbit anti-human HER2 antibodies,
which specifically targets a biomarker in breast cancer cells, and the final probe offers
LSPR positions around 430 nm, 500 – 550 nm (shoulder peak), and 690 nm. EVs from a
breast cancer cell line (SKBR3) and normal lung fibroblasts (MRC5) were used as models
for cancerous and normal cells, respectively, and probed with a 632.8 nm laser. The
characteristic peak for DTNB is located at 1327 cm-1, which corresponds to the nitro group
symmetric stretching, and was found to decrease with decreasing EV concentration, while
the controls were associated with low intensity, and the detection limit was estimated to be
1200 EVs. In fact, the DTNB signal intensity from the cancer-derived EVs was
approximately 2.5 times stronger than the normal EVs, and even 3.8 times stronger when
cell numbers were normalized, since cancerous cells tend to secrete more EVs than their
normal counterparts.
Another sandwich-type immunocomplex was proposed by Wang et al., which consists of
MBs covered by a silica layer and gold shell and modified by aptamers of CD63 via Au-S
bonds for EV capture (Figure 2-11A).[120] Three different SERS probes based on AuNPs
were implemented with varying aptamers, each targeting a specific cancer type, and Raman
reporters for multiplexed detection. For the detection of breast cancer EVs derived from
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the SKBR3 cell line, AuNPs were modified with the aptamer of HER2 (i.e., breast cancer
biomarker) and Raman reporter DTNB, as in the previous paper reviewed. For the detection
of colorectal cancer EVs derived from the T84 cell line, AuNPs were modified with the
aptamer of CEA, which binds to a carcinoembryonic antigen overexpressed in T84 cells,
and Raman reporter 2,7-mercapto-4-methylcoumarin (MMC). MMC has a characteristic
peak located at 1170 cm-1, corresponding to the triangular and symmetric benzene ring
breathing deformations including the in-plane deformations of the C(O)-O group. Lastly,
for the detection of prostate cancer EVs derived from the LNCaP cell line, AuNPs were
modified with the aptamer of PSMA, which binds to a prostate-specific membrane antigen,
and Raman reporter 2-naphthalenethiol (2NAT), which has a characteristic peak at 1378
cm-1 corresponding to ring stretching. Each EV type was analyzed by SERS using a 632.8
nm excitation wavelength, and the detection limits for the SKBR3 EVs, T84 EVs, and
LNCaP EVs were estimated to be 32 EVs μL-1, 73 EVs μL-1, and 203 EVs μL-1,
respectively. In this case, characteristic peaks were found to decrease with increasing EV
concentration. The performance of the model was further validated with clinical samples
(3 cancer patients and 1 healthy individual) (Figure 2-11B), but accuracy was not reported,
and limited sample sizes were used in both cell line and clinical cases.
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Figure 2-11: Sandwich-type immunocomplex for the analysis of breast cancer,
colorectal cancer, and prostate cancer-derived EVs. (A) Schematic illustration of the
fabrication of capture probes and SERS probes, as well as the formation of the
immunocomplex and acquisition of SERS spectra. (B) Simultaneous detection of
breast cancer, colorectal cancer, and prostate cancer markers demonstrated using
patient-derived EVs. Adapted with permission from reference [120] (copyright 2018
Royal Society of Chemistry).
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A sandwich-type immunocomplex that targets EVs via bivalent cholesterol-labelled DNA
anchors has been proposed by Tian et al.[121] Herein, the capture probes consist of MBs
functionalized with anti-CD9, and DNA-labelled SERS probes consist of AuNSs modified
with Raman reporter 4-mercaptobenzoic acid (MBA) and covered with a gold nanoshell.
The SERS probe allows for monitoring of EVs via the characteristic 1078 cm -1 peak and
offers an LSPR around 615 nm. The probes were tested with EVs derived from liver cancer
cell line HepG2. The authors observed the characteristic MBA peak only in the presence
of EVs, since the immunocomplex cannot form without them. The detection limit was
estimated to be 27 particles μL-1, far more sensitive than commercially available methods
and even other SERS techniques. Human serum samples from 3 liver cancer patients and
3 healthy individuals were also used to validate this method, and EVs from these samples
were quantified using a calibration equation established by the cell line model. The EV
amounts were further validated by the standardized method qNano, and the results were in
agreement. Although a lower EV count was identified in the healthy patients compared to
the cancer patients, a diagnostic threshold was not established, and the diagnostic potential
of the biosensor was therefore not quantified.
An EV-probe assembly was detailed by Jiang et al., in which DTNB-modified AuNPs were
functionalized with locked nucleic acids (LNAs) targeting miRNA-10b.[134] Rather than
targeting EVs via surface interactions, the LNA-modified SERS tags are transported into
EVs by incubation (Figure 2-12A), which the authors confirmed with TEM imaging and
fluorescence measurements. These SERS probes also provided LSPR modes around 520
nm and 625 nm. Fe3O4 core-TiO2 shell MBs were used for EV capture, which can
concentrate EVs with an efficiency of 96.5 % in 10 minutes with the application of an
external magnet due to the high specificity binding between TiO2 and the phosphate groups
on EV membranes. EVs from pancreatic ductal adenocarcinoma (PDAC) cells (PANC-01)
and normal pancreatic cells (HPDE6-E7) were probed under a 785 nm excitation
wavelength laser. The characteristic DTNB peak was found to be 3-fold higher in the
cancer-derived EVs compared to the normal EVs (Figure 2-12B). The authors
demonstrated high specificity by distinguishing the target miRNA-10b from the single base
mismatched miRNA-10a and estimated the detection limit to be 0.21 fM. Since miRNA10b has also been reported to be overexpressed in colorectal cancer cell EVs, the authors
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further validated miRNA-10b detection with EVs derived from the colorectal cancer cell
line HCT116 and the normal colonic epithelial cell line CCD841. The authors went on to
monitor miRNA-10b levels in sera of 15 PDAC patients and 15 individuals and found that
the characteristic peak intensity in the case of the cancer patients was 3-fold higher
compared to the healthy individuals (Figure 2-12C). While the authors assessed the
diagnostic capabilities of the assembly with an ROC curve and found the AUC to be quite
high at 0.996, accuracy, sensitivity, and specificity were not reported.

Figure 2-12: EV-probe assembly for the SERS analysis of pancreatic cancer-derived
EVs. (A) Schematic illustration of the uptake of SERS probes into EVs and the affinity
of Fe3O4 core-TiO2 shell MBs to the EV surface. (B) SERS maps of normal pancreatic
cell line-derived EVs (left) and pancreatic cancer cell line-derived EVs (right),
highlighting the higher SERS intensity observed when the target is present. (C)
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Higher characteristic peak intensity is also observed with EVs derived from clinical
samples. Adapted with permission from reference [134] (copyright 2021 American
Chemical Society).

2.4.4

Sandwich-Type Immunoassays for Indirect Sensing

One sandwich-type immunoassay reported by Li et al. consists of a glass slide modified by
the self-polymerizing polydopamine (PDA) and antibodies (e.g., anti-MIF) for EV
capture.[135] PDA provides a biocompatible, uniform layer into which antibodies can be
homogeneously encapsulated with high efficiency.

The SERS probes utilized were

multilayered, consisting of an 18 nm gold core, silver shell, Raman reporter 4aminobenzenethiol (pATP), PDA, and antibodies, and provided LSPR modes around 400
nm and 500 nm. The Raman reporter has a characteristic peak around 1072 cm-1,
corresponding to the benzene ring breathing vibration, and the PDA layer served to protect
the silver layer from oxidation. EVs from the pancreatic cancer cell line PANC-01 and
normal cell line HPDE6-C7 were analyzed by SERS using a 785 nm excitation wavelength,
and the detection limit was estimated to be 544 particles μL-1. The biosensor was further
tested with EVs derived from patient serum samples (71 PDAC patients and 32 healthy
individuals) and was able to distinguish the serum of cancer patients from that of healthy
donors, but with low sensitivity (62.5 %) and low specificity (76.2 %). The authors noted
that the biosensor was even able to distinguish 37 patients with higher stage (P3) stage
tumors from 4 patients with lower stage (P1-2) tumours. Although the sensitivity was high
in this instance (95.7 %), the specificity was again found to be low (53.4 %). When the
authors attempted to distinguish 10 patients with metastatic cancer from 61 patients with
nonmetastatic cancer, low sensitivity and specificity were again achieved, at 53.3 % and
73.9 %, respectively. Additionally, the laser excitation wavelength at 785 nm was not well
matched to the LSPR bands of the biosensor, which poses the question of whether the
SERS effect was indeed observed.
Another sandwich-type immunoassay was proposed by Kwizera et al. consisting of
antibody (anti-CD63) arrays on a gold-coated slide for specific EV capture.[136] The SERS
probes consisted of AuNRs of 35 nm length and 12 nm width capped with cetrimonium
bromide (CTAB) and coated with an organic dye, QSYTM 21 carboxylic acid-succinimidyl
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ester (QSY21), as a Raman reporter, providing an LSPR band around 720 nm. Cationic
CTAB was chosen to allow for the electrostatic adsorption of the SERS probes onto the
anionic lipid EV bilayer, and to provide a hydrophobic pocket into which the hydrophobic
Raman reporter could be loaded. QSY21 was chosen as the Raman reporter for its
nonfluorescent properties and fingerprinting signal at 1497 cm-1. EVs from three breast
cancer cell lines (MDA-MB-231, MDA-MB-468, and SKBR3) were analyzed with the
normal breast cell line MCF12A used as a control. The EVs were probed with a 785 nm
excitation wavelength laser, and the detection limit was estimated to be 2000 EVs μL-1,
approximately 500 times lower than the estimated concentration of EVs in plasma. MDAMB-231 was used as the model cell line to determine protein expression in breast cancer
EVs by examining levels of the epithelial marker EpCAM, breast cancer markers CD44,
HER2, EGFR, and IGFR, and exosome markers CD9, CD63, and CD81. MDA-MB-231derived EVs displayed a high expression of CD44, and low expression of EpCAM and
other breast cancer markers, consistent with literature and validated with the gold standard
ELISA. MDA-MB-468-derived EVs also displayed high EpCAM expression and moderate
HER2 expression, while SKBR3-dervied EVs displayed high EpCAM and HER2
expressions. The control EVs were also positive for EpCAM, but with a much lower level
compared to the cancer-derived EVs. All EVs also displayed high exosome marker
expressions. The authors further evaluated the biosensor with plasma samples from 10
breast cancer patients (2 stage I patients, 2 stage II patients, and 6 stage III patients) and 5
healthy individuals. The cancer-derived EVs showed much higher expressions of EpCAM
and HER2 compared to the healthy controls, whereas the differences in CD44 among all
patients were less noticeable. Both cancer-derived EVs and normal EVs additionally
displayed strong exosomal marker expressions. However, accuracy, sensitivity, and
specificity were not reported, and a limited data set was evaluated. The authors also noted
that EV isolation from plasma was required prior to analysis.
An immunoassay targeting miRNAs via specific LNA probes was proposed by Lee et
al.[137] Flocked gold nanopillars with 200 nm diameter and 800 nm height were used as a
SERS substrate, fabricated by the RIE of silicon followed by electron beam evaporation of
gold (Figure 2-13A). The nanopillars are termed flocked since the pillars lean towards
each other due to a capillary force developed during solvent evaporation, improving the
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coupling of localized surface plasmons by reducing the gap between nanopillars
(approximately 100 – 200 nm) (Figure 2-13B,C). Each LNA probe used targets miRNAs
closely related to breast cancer (miRNA-21, miRNA-222, miRNA-200c). The probes were
labelled with Cy3 dye, providing a characteristic peak at 1150 cm-1. EVs from luminal
subtype (MCF7, BT474), HER2+ subtype (SKBR3, AU565), and TN subtype (MDA-MB231, HCC1143) breast cancer cell lines were analyzed by SERS using a 785 nm excitation
wavelength. The probes were able to discriminate single base-mismatched miRNAs, and
the detection limit was estimated to be 1 aM. By monitoring SERS signal intensity, the
authors found that miRNA-21 was significantly higher in the luminal and TN subtypes
compared to the HER2+ subtype, and miRNA-222 and miRNA-200c were also clearly
distinguishable. These findings were also validated with the standard quantitative reverse
transcription-polymerase chain reaction (qRT-PCR). While the authors proposed a highly
selective and sensitive platform for breast cancer diagnosis, the study lacked a normal
control group, so the diagnostic capability could not be assessed.

Figure 2-13: Flocked gold nanopillars for the SERS analysis of breast cancer-derived
EVs. (A) Schematic illustration of the fabrication and functionalization of the
nanopillars. (B) Top-view (left) and tilt-view (right) SEM images of upright
nanopillars. (C) Top-view (left) and tilt-view (right) SEM images of head-flocked
nanopillars. Adapted with permission from reference [137] (copyright 2019 WileyVCH).
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A microfluidic sandwich-type immunoassay device named the EV phenotype analyzer chip
(EPAC) was introduced by Wang et al.[138] Capture substrates consisted of a series of
asymmetric gold electrodes fabricated by photolithography, which allowed for nanoscopic
lateral fluid flow, and were aligned with microfluidic channels fabricated by soft
lithography. The substrate or “chip” was functionalized with capture antibodies anti-CD63
and anti-MSCP, although a lower detection limit could be achieved with the anti-MSCPfunctionalized EPAC. Four SERS tags based on 60 nm AuNPs were implemented, each
targeting a single biomarker. Raman reporters MBA and DTNB, described above, were
used to target markers MCSP and ErbB3, respectively. Raman reporters 4mercaptopyridine

(MPY)

and

2,3,5,6-tetrafluoro-MBA

(TFMBA),

which

have

characteristic peaks at 1000 cm-1 and 1375 cm-1, respectively, targeted markers LNGFR
and MCAM. EVs from melanoma cell line SK-MEL-28 were analyzed under a 632 nm
excitation wavelength laser. SK-MEL-28 cells are expected to have high expressions of
MCSP and MCAM and low expressions of ErbB3 and LNGFR. As a negative control, EVs
from breast cancer cell line MCF7 were utilized, which are expected to have low
expressions of all four markers. Indeed, SK-MEL-28 EVs demonstrated quantifiable signal
while negligible signal was observed with MCF7-derived EVs. The response of EVs from
SK-MEL-28 along with EVs derived from two other BRAF mutation cell lines (LM-MEL33 and LM-MEL-64) when treated with a BRAF inhibitor drug was also monitored. Two
control groups were also used, including LM-MEL-64 EVs without treatment and NRAS
mutation cell line LM-MEL-35, which is not expected to respond to this type of drug
treatment. After 30 days of treatment, EVs from all three BRAF mutation cell lines showed
obvious phenotypic changes (quantified by LDA), while the negative control EVs
displayed no phenotypic changes. The authors further challenged the biosensor with patient
plasma-derived EVs (11 melanoma patients and 12 healthy individuals), and found that
based on MCSP levels, melanoma patients could be differentiated from healthy controls.
These findings were also validated with the standard ELISA by monitoring ErbB3 levels.
Phenotypic changes of these EVs in response to drug treatment was also monitored, but in
some cases, changes were not observed by SERS despite radiological imaging confirming
disease progression. The authors therefore highlighted the need to further study and
evaluate the choice and number of biomarkers implemented in the EPAC.
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Probing DNAs immobilized onto gold octahedra with an edge length of 50 nm have been
introduced by Kang et al. for the analysis of miRNA-7a in breast cancer EVs.[139] Gold
octahedral NPs are able to self-assemble into a hexagonal arrangement in liquid and were
transferred to a solid (silicon) substrate (Figure 2-14A), providing a uniform electric field
distribution and an LSPR mode around 666 nm. The SERS tag consisted of a Cy5 dyelabelled oligonucleotide probe was designed into a hairpin structure and immobilized on
the array via the Au-S bond. Cy5 has prominent spectral peaks at 938 cm-1 (C-H
deformation), 1120 cm-1 (C-H in-plane bending), 1230 cm-1 (C-N stretching), 1359 cm-1
(methine chain deformation), 1467 cm-1 (C=C ring stretching), and 1597 cm-1 (C=N
stretching). Additionally, Cy5 has an absorption centered around 660 nm, overlapping with
the resonance of the array and leading to coresonance. When the let-7a target is present,
the probe hybridizes with let-7a and opens its hairpin structure, forcing Cy5 away from the
SERS-active surface and resulting in a signal intensity decrease across all Cy5 peaks
(Figure 2-14B,C). The detection limit was estimated to be 5.3 aM, and the authors also
demonstrated specificity by introducing other miRNAs to the biosensor such as miRNA21, miRNA-375, let-7fi (4 base mismatch), let-7i (2 base mismatch), and let-7f (1 base
mismatch). EVs from breast cancer cell line MCF7 and normal breast cell line MCF-10A
were analyzed using an excitation wavelength of 633 nm, and the expression of let-7a in
MCF7-derived EVs was found to be 3.27-fold higher compared to MCF-10A-derived EVs.
The authors also monitored the response of let-7a levels to treatment with the
chemotherapeutic drug 5-fluorouracil for 48 hours and found a higher intensity change in
treated EVs compared to non-treated EVs, which was validated with qRT-PCR. However,
at this stage, the authors have not challenged their biosensor with clinical samples.
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Figure 2-14: (A) TEM image of a gold octahedral self-assembled monolayer. (B)
Schematic illustration of the sensing principle of the structure, in which the hairpin
structure P opens upon hybridization with let-7a, forcing the Cy5 molecules (red star)
farther away from the gold surface. (B) SERS spectra of Cy5 in the (a) absence and
(b) presence of let-7a, highlighting the change its change in intensity when the target
is present. Adapted with permission from reference [139] (copyright 2021 American
Chemical Society).

2.5 Summary
The focus of this chapter was to provide detailed background information of techniques
utilized throughout this thesis. The principles of Raman spectroscopy and SERS were
introduced in this chapter. Raman spectroscopy and SERS were then explained in the
context of biological systems, reviewing expected peaks arising from biological
macromolecules and explaining how spectra are typically used and analyzed in biological
applications. PCA was introduced and explained in detail, since it is the dimensionalityreduction method used to process SERS spectra in this thesis. Since machine learning was
used in series with PCA for EV classification in this thesis, the process of machine learning
and various algorithms that can be used were also reviewed. Finally, various SERS probes
and platforms that have been reported in literature were thoroughly reviewed, highlighting
both recent advances in the field and limitations of current methods.
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Chapter 3

3

Characterization of Extracellular Vesicles Derived from
Mesenchymal Stromal Cells by Surface-Enhanced
Raman Spectroscopy

A version of this work has been published in the journal Analytical and Bioanalytical
Chemistry: Ćulum, N. M.; Cooper, T. T.; Bell, G. I.; Hess, D. A.; Lagugné-Labarthet, F.
Characterization of Extracellular Vesicles Derived from Mesenchymal Stromal Cells by
Surface Enhanced Raman Spectroscopy. Anal. Bioanal. Chem. 2021, 413, 5013-5024. This
chapter has been reproduced with permission from Springer Nature.
In this chapter, EVs released by MSCs derived from bone marrow (BM-MSC) and
pancreatic tissue (Panc-MSC) are characterized by SERS. The SERS platform fabricated
by electron-beam lithography consists of gold nanohole arrays of varying size (100 – 1000
nm) and shape (triangles, circles, and squares). While BM-MSC EVs have been previously
investigated by conventional Raman spectroscopy, they have not to date been characterized
by SERS. Panc-MSC EVs have indeed been characterized by SERS in the past, although
this study looked into a larger sample size. Discussed in this chapter are the main
compositional differences between BM- and Panc-MSC EVs determined by PCA. Machine
learning was implemented in order to discriminate the two groups from each other and
demonstrate the classification power of the platform.

3.1 Introduction
An overview of MSC-derived EVs and their applications was provided in Section 1.2.1.
Briefly, MSCs have been shown to induce cellular changes in nearby cells through the
release of chemical messengers, known as paracrine signaling, particularly via their
secreted EVs.[1] EVs released from MSCs are potent cell-free regenerative and restorative
agents that are effective in neural,[2-4] myocardial,[5-7] hepatic,[8,9] renal,[10-12] cutaneous,[1315]

skeletal,[16,17] cartilage,[18,19] and muscular regeneration.[20,21] In particular, BM-MSCs

have been widely studied due to the regenerative potential of their secreted EVs. For
example, BM-MSC EVs have been shown to reduce neuroinflammation in traumatic brain
injuries,[22] promote survival of retinal ganglion cells and the regeneration of their axons,[23]
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suppress inflammation response in acute myocardial infarction,[24] and promote the
proliferation of cisplatin-damaged proximal tubular epithelial cells.[25] However, to be used
in therapeutic and regenerative practices, sensitive and reproducible characterization
protocols must be established. The characterization of EVs is challenged by their nanoscale
size (30 – 150 nm for exosomes and 100 – 1000 nm for microvesicles) and heterogeneity
in terms of size range, morphology, molecular composition, and biogenic mechanisms.[2628]

While SERS has been extensively used in the characterization of cancer-derived EVs, its
application in the characterization of MSC EVs has been largely underexplored. Although
BM-MSC EVs have been characterized by Raman spectroscopy, none to date to our
knowledge have been characterized using SERS.[29,30] Gualerzi et al. conducted a Raman
spectroscopy study comparing EVs isolated from BM-MSCs, adipose tissue MSCs, as well
as EVs released from dermal fibroblasts.[29] The authors reported decent discriminatory
power using PCA-LDA with 93.7 % accuracy, 88.6 % sensitivity, and 95.1 % specificity.
However, the Raman spectra reported in this work were of low resolution and quality, and
required baseline correction to remove a fluorescence background, and were bulk
measurements of EVs, as opposed to single or near-single EV detection. The subsequent
study published compared Raman spectra of BM-MSC EVs and EVs released from human
liver stem cells.[30] Although the main purpose of this study was to assess EV purity from
various isolation protocols (i.e., ultracentrifugation and size-exclusion chromatography) by
PCA-LDA, the authors reported that both EV sources could be discriminated from non-EV
cell fractions with 97 % accuracy. The main limitation of this study again was the lowquality Raman spectra reported due to the fluorescent nature of biological samples.
In this proof-of-concept study, we have investigated EVs derived from BM-MSCs as well
as Panc-MSCs by SERS. Previous preliminary work reported from our group has
demonstrated the feasibility of using these platforms for SERS characterization of PancMSC EVs, but a small sample size was reported.[31] Herein, we have built on these concepts
and further explored the capacity of these nanohole arrays to trap, detect, and differentiate
EVs from these two sources. We have fabricated plasmonically active gold nanohole arrays
of varying size (100 – 1000 nm) and shape (circles, squares, and triangles) by electron-
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beam lithography (EBL) that are capable of EV trapping and signal enhancement for SERS.
Reported in this chapter are spectral fingerprints associated with both EV sources. The
main compositional differences between Panc-MSC and BM-MSC EVs were determined
by PCA, and machine learning was further employed to differentiate the two groups with
high accuracy, sensitivity, and specificity.

3.2 Methods
3.2.1

Nanohole Array Fabrication by EBL

Nanohole arrays were fabricated using the protocol established by Kaufman et al.[31] A
negative-tone resist, ma-N 2405 (Microchem), was spin-coated onto reactive O2-cleaned
glass coverslips at 3000 rpm for 45 seconds, corresponding to a thickness of approximately
500 ± 50 nm, then baked at 90 °C for 90 seconds. AquaSAVETM conductive polymer
(Sigma-Aldrich) was then spin coated at 1000 rpm for 45 seconds and baked at 90 °C for
45 seconds. EBL and SEM imaging were performed using a LEO 1530 scanning electron
microscope (Zeiss) with a 30.0 kV voltage, 10.0 μm aperture, and 30.0 – 50.0 pA current.
Arrays of varying shape (square, circle, and triangle) and size (0.1 – 1.0 μm in 0.1 μm
increments, 1.0 μm width between holes) were written using ELPHY Quantum software
(Raith Nanofabrication). All patches measured 50 × 50 μm2. Following beam exposure,
substrates were soaked in DI water to remove the conductive layer. Samples were
developed in MF-319 (MicroChem) for 40 seconds, soaked in DI water, and air dried to
avoid collapsing the nanopillars. Samples were subjected to an O2 plasma descum process
(Trion Technology) for 60 seconds to remove residual resist surrounding the nanopillars.
A 3 nm adhesion layer of titanium was then deposited onto the samples followed by 30 nm
of gold by electron beam evaporation (Angstrom Engineering). For lift-off, samples were
exposed to Remover-PG (MicroChem) and heated to 80 °C for 2 hours. Remover-PG was
removed from the samples by soaking in a 1:3 solution of methyl isobutyl ketone (MIBK)
and isopropanol (IPA). Samples were then rinsed with IPA and dried under N2. For final
cleaning, samples were immersed in Nano-Strip® (Cyantek) and heated to 80 °C for 30
minutes, then DI water for 15 minutes, and dried under N2. Finally, samples were again
subjected to O2 plasma for 5 minutes to remove any remaining resist from the holes.
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3.2.2

Absorption Measurements

Vis-NIR spectra of gold nanohole arrays were obtained with a homebuilt setup consisting
of an HL-2000 halogen lamp (Ocean Optics), which covers a spectral range of about 400
– 1000 nm, coupled to an inverted optical microscope by a 100 μm optical fiber. The source
beam was first expanded by a 10 × objective (N.A. = 0.25), recollimated using 20 ×
objective (N.A. = 0.40), and finally collected by a 20 × objective (N.A. = 0.50). The
resulting spot sizes were approximately 50 μm in diameter, covering the surface of a single
array. Scattered light was then analyzed with a USB 4000-Vis-NIR-ES spectrometer
(Ocean Optics).

3.2.3

Cell Culture

Human bone marrow aspirates were obtained from healthy donors with informed consent
from the London Health Sciences Centre, Western University (London, ON) following
protocol REB#12934. BM-MSCs were established and cultured in AmnioMax-C100TM
media with AmnioMaxTM C100 supplement (Life Technologies) as previously described
by Sherman et al.[32] Ricordi-chamber isolated human islets were obtained through the
Integrated Islet Distribution Program (USA) for the establishment of Panc-MSCs as
previously described by Cooper et al.[33] 200 islet equivalents were plated in RPMI 1640 +
10% fetal bovine serum (FBS) for up to 7 days. Between 5 – 7 days, adherent fibroblastlike cells were separated from non-adherent islets by media aspiration followed by
trypsinization and filtration using a 40 μm cell strainer. Single cell suspensions were
subsequently reseeded on tissue culture plastic at 4000 cells/cm2 and expanded in
Amniomax-C100TM with AmnioMaxTM E100 supplement (Life Technologies).

3.2.4

EV Isolation

EVs were isolated by ultrafiltration as previously described by Cooper et al.[34] Conditioned
media (CM) was generated by culturing BM-MSC and Panc-MSC to ~80% confluency,
rinsed 3 times with pre-warmed phosphate buffer solution (PBS), and switched to basal
AmnioMaxTM C100 media (Life Technologies) without supplement. Media was collected
after 24 hours of cell culture. Cell debris were removed by centrifugation for 10 minutes at
600 × g. Cell-free CM was concentrated by centrifugation in 100 kDa centrifuge filter units
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for 20 minutes at 2800 × g. A 20 mL solution was concentrated in a single unit, requiring
two centrifugations, producing a final volume of 120 μL. After the second centrifugation,
10 mL of 0.22 μm-filtered PBS was used to wash out residual phenols, proteins, and salts.
EV samples were collected and placed into Eppendorf tubes and stored at -20 °C for up to
one month.

3.2.5

AFM Measurements

Purified EV solutions were diluted (1:20) in Milli-Q water. 10 μL of the dilute EV samples
were drop-casted onto chemically cleaned glass coverslips (22 mm × 22 mm × 0.15 mm)
and dried overnight in a biological safety cabinet. Scans were obtained using a BioScope
Catalyst atomic force microscope (Bruker). NCLR-50 Silicon probes (Nanoworld) with a
force constant of 48 N/m and a resonance frequency of 190 kHz were employed under
tapping mode. Height images were recorded at 256 × 256 pixels and a scan rate of 0.50 Hz.
Imaging processing was subsequently performed using Gwyddion software.

3.2.6

SERS Measurements

Concentrated EV samples were diluted 1:20 with Milli-Q water. 10 – 20 μL of dilute EV
samples were drop-cast onto nanohole arrays. EV-water solution was removed from the
array using cohesive properties allowed by a Kimwipe absorbent paper (Kimberly-Clark
Inc.). The edge of the absorbent paper was placed on the corner of the solution droplet,
allowing solution removal via capillary action. This capillary flow also induces EVs to
locate and stay in the nanoholes. Lastly, EV solutions were allowed to dry for 15 – 30
minutes prior to SERS measurements. SERS spectra presented in Figure 3-5 were
acquired with a LabRAM HR spectrometer (Horiba Scientific) using a 632.8 nm excitation
laser source, 600 grooves/mm grating, 100 × objective (N.A. = 0.9), and 200 μm pinhole.
Laser power was set to 2.5 mW with an acquisition time of 60 seconds per spectrum. SERS
spectra presented in Figure 3-3 and Figure 3-6 were extracted from SERS maps that were
acquired with an XploRATM PLUS spectrometer (Horiba Scientific) using a 785 nm
excitation laser source, 600 grooves/mm grating, 100 × objective (N.A. = 0.9), and 100 μm
pinhole. Laser power was set to 5 mW with an acquisition time of 4 seconds per spectrum.
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3.2.7

Statistical Analysis and Machine Learning

All spectra were normalized prior to PCA. The first 19 PCs were selected to explain 98%
of variance among spectra. After score plots were constructed, 95% confidence ellipses
were fitted around each cluster type. The first 19 PCs were then used as input data for five
different machine learning algorithms: logistic regression, support vector machine, random
forest, Naïve Bayes, and CN2 rule induction. In each machine learning case, models were
tested using leave-one-out cross validation. PCA and machine learning were performed
using Orange software (version 3.27.1).

3.3 Results and Discussion
3.3.1

Nanohole Array Fabrication and Characterization

EBL is a nanofabrication technique used to create nanostructures with 20 nm spatial
resolution. Nanostructures are fabricated by scanning a focused beam of electrons from an
SEM onto an electron-sensitive photoresist, which undergoes chemical changes in exposed
areas. The EBL nanofabrication process is illustrated in Figure 3-1A. Some substrates,
such as the glass coverslips used here, additionally require the application of a conductive
layer on top of the resist to prevent charging on the substrate surface during the inscription
of the pattern, which minimizes the loss of resolution when the substrate is exposed to the
electron beam. Following exposure, the substrate is developed in a chemical bath to remove
some of the resist and reveal the desired pattern. For the purpose of fabricating nanohole
arrays, a negative-tone resist is desired, and ma-N 2405 was used. Negative-tone resists
undergo cross-linking in exposed areas, and non-exposed regions are removed during
development, thus producing the reverse or “negative” image of the final pattern. For
nanohole arrays, this “negative” image translates to nanopillar arrays (Figure 3-1B). Since
the objective of the work is to use the nanohole arrays in SERS sensing, metals must be
deposited onto the developed substrate for the propagation of plasmons. Gold was selected
for these experiments due to its greater stability in air compared to other common SERSactive metals such as silver and copper. Finally, the metallic substrate is placed into a
chemical bath to remove any remaining resist and reveal the final nanoholes in a process
called lift-off (Figure 3-1C).
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Figure 3-1: (A) Schematic illustration of nanohole array fabrication by EBL using a
negative-tone resist, with example SEM images of 700 nm circular arrays (B) before
lift-off and (C) after lift-off (scale bars = 2 μm).
Gold nanohole arrays of varying size (100 – 1000 nm) and shape were fabricated by EBL,
imaged by SEM, and characterized by vis-NIR spectroscopy. Shapes explored for these
arrays consisted of triangles (Figure 3-2A,D), squares (Figure 3-2B,E), and circles
(Figure 3-2C,F). Fallen nanopillars or nanocaps are visible on the smaller-sized arrays
(Figure 3-2D-F) and not on the larger-sized arrays (Figure 3-2A-C) since negative resists
become increasingly difficult to remove as hole size decreases. Nevertheless, smaller
arrays are still suitable for EV capture if the nanocaps do not collapse directly into the
holes. Absorption measurements were subsequently performed to determine the position
of their plasmonic resonances, as shown on the triangular arrays (Figure 3-2G,H). Two
resonance wavelengths are observed: one around 650 – 690 nm, and another around 750 –
780 nm. Similar results were observed with the circular and square arrays, and is consistent
with the results previously reported by our group.[31] When the excitation wavelength
matches their resonance wavelengths (i.e., 633 and 785 nm), the conduction electrons at
the metal surface of the arrays are driven to collective oscillation at a frequency referred to
as the LSPR.[35] The higher energy band around 650 – 690 nm is generally referred to as
the quadrupolar resonance, while the lower energy band around 750 – 780 nm is referred
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to as the dipolar resonance. Consequently, large enhancements of the local electromagnetic
fields of radiation are confined at the vicinity of the nanoholes. Since the EVs are smaller
in diameter compared to the hole sizes, we expect EVs to be captured by the nanoholes and
their Raman signals to be enhanced as a result.

Figure 3-2: SEM images of 1000 nm (A) triangular, (B) square, and (C) circular
arrays, and 500 nm (D) triangular, (E) square, and (F) circular arrays (scale bars = 1
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μm). (G) Background-corrected absorption spectra of 500 – 1000 nm triangular
arrays and (H) corresponding raw absorption spectra.
The trapping capabilities of these nanohole arrays have been previously published by our
group, both by polystyrene beads as proof-of-concept, as well as with EVs themselves.[31]
Trapping of the EVs is enabled by the flow of the EV-containing solution and the size
match between the EVs and the nanohole cusps. However, trapping of small EVs cannot
be observed optically due to the diffraction limited spatial resolution of our optical
measurement. Therefore, blind SERS mapping over large areas of the nanohole arrays is
necessary to reveal which holes are filled with one or more EVs (areas with signal) and
which holes are empty (areas without signal). SERS mapping experiments showed that
approximately 12 % of the holes were occupied by one or more EVs (Figure 3-3). For
SERS of EVs, the circular arrays were the least preferential due to a lower throughput from
the EBL process compared to the triangular and square arrays. This lower throughput could
potentially be due to the fact that the corners of the triangles and squares provided more
anchoring points for the pillars with three and four points, respectively. Conversely, the
highest throughput of arrays was achieved with the square arrays, allowing more
opportunity for the square arrays to capture EVs. Therefore, square arrays were generally
preferred for SERS experiments. By utilizing these SERS platforms in conjunction with
lasers of excitation wavelengths that match their LSPRs, we are able to study samples with
inherently weak Raman signals without the need to increase laser power or accumulation
time, which is likely to burn the samples, or the need to use a higher energy laser
wavelength (i.e., green laser), which is likely to induce high background fluorescence.[36]
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Figure 3-3: (A) SERS map comprised of 100 spectra of BM-MSC EVs over an area of
16 1.0 μm-sized square nanoholes, where high intensity areas (blue) correspond to
trapped EVs and low intensity areas (red) correspond to empty holes. (B) SERS map
from (A) smoothed and overlaid with an optical image of the array and (C)
corresponding spectra of points (1) – (3) from (B), with spectra shifted vertically for
clarity.

3.3.2

EV Characterization

AFM was employed for EV imaging and height quantification since it causes minimal
deformations to the soft EV surface when scanning in tapping mode. For AFM imaging,
dilute solutions of EVs were drop-casted on clean glass coverslips and allowed to dry.
AFM scans of EVs isolated from both Panc-MSC (Figure 3-4A) and BM-MSC (Figure 34C) revealed small, quasi-spherical objects on the substrate surface. A cross-section of one
of these features is shown in Figure 3-4B. The average height of the adhered EVs from the
Panc-MSC samples measured over 106 individual EVs was 210 ± 40 nm, with the size
distribution ranging from 110 – 330 nm (Figure 3-4D). Similarly, the average height of
the adhered EVs from the BM-MSC samples was 190 ± 50 nm, with a size distribution of
50 – 300 nm. Recalling that microvesicles range in diameter from 100 – 1000 nm, these
distributions are well within the accepted EV size range.
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Figure 3-4: (A) (5 × 5) μm2 AFM scan of Panc-MSC EVs on a bare glass coverslip and
(B) the cross-section of a single EV, as indicated by the white line in (A). (C) (1 × 1)
μm2 AFM scan of an individual BM-MSC EV on a bare glass coverslip. (D) A
histogram representing the height distribution of a Panc-MSC sample containing 106
EVs.
Initial SERS characterization of EVs from the Panc-MSC sample was conducted with an
excitation wavelength set at 632.8 nm, which utilizes the quadrupolar resonance of the
nanohole arrays. Spectra were acquired by focusing a 632.8 nm laser with a 100 × objective
(N.A. = 0.90) on holes presumably containing EVs, and a background spectrum was
recorded by focusing the same laser off the array on flat gold. The resulting spectra of three
individual EVs reveal an abundance of peaks in the 700 – 1800 cm-1 fingerprint region, as
expected since this is a significant Raman spectral window for biological samples, whereas
none are visible in the background spectrum (Figure 3-5). Since the LSPR decays
exponentially away from the platform surface, the effective sensing zone of the plasmonic
arrays is confined within the first 10 – 20 nm away from the metal surface.[37] Since plasma
membranes are typically about 5 nm thick, we expect to detect not only SERS signals
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corresponding to the surface content of the EVs (i.e., surface proteins and lipids), but also
the SERS signals of their cargo (i.e., proteins and genetic material). The analysis of the
collected spectra showed that some Raman modes are common among the three EVs,
which are summarized in Table 3-1. Protein peaks are observed at 1052 cm-1 and 1242 cm1

which can be assigned to C-O/C-N stretching and amide III, respectively. Additionally,

amino acid peaks are present at 1210 cm-1, which is found in tyrosine and phenylalanine,
and at 1580 cm-1, which is found in phenylalanine. Nucleic acid peaks are present at 791
cm-1 and 1509 cm-1, corresponding to pyrimidines and adenine/cytosine, respectively. The
peak present at 1308 cm-1 can be attributed to the CH2/CH3 twisting, bending, or wagging
in lipids or collagen. Although these peaks are shared in a couple of spectra, there is still
variety in the spectra in terms of peak positions and intensities, which can be attributed to
the molecular heterogeneity of EVs.

Figure 3-5: Three SERS spectra of Panc-MSC EVs acquired with a 632.8 nm laser
with a background spectrum for comparison and common peaks highlighted in blue.
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Table 3-1: Assignments of common peaks shared among Panc-MSC EV spectra from
Figure 3-5.
Peak (cm-1)

Presumed Origin

Ref. Peak (cm-1)

Ref.

791

Pyrimidine

791

[38]

1052

C-O/C-N stretch in proteins

1053

[38]

1193

Ring stretch, CH bend, CH2 twist

1194

[39]

1210

C-C6H5 stretch in tyrosine and

1210

[38]

phenylalanine
1242

Amide III

1243

[38,40]

1308

CH2/CH3 twisting, bending, and wagging

1308

[38]

in lipids or collagen
1413

Ring stretch

1412

[38]

1509

Ring breathing mode of adenine and

1510

[38]

1580

[38]

cytosine
1580

C-C stretch and C=C bend of
phenylalanine

While we were able to collect spectra for the Panc-MSC EVs at 632.8 nm, the spectral
acquisition for the BM-MSC EVs was unsuccessful at the same wavelength due to the
presence of a fluorescence background. To mitigate the background fluorescence, we
switched to a 785 nm laser, thus exploiting the dipolar resonance of the nanohole arrays.
Data sets for Panc-MSC and BM-MSC EVs comprised of 25 and 19 SERS spectra,
respectively, were obtained with a 785 nm excitation laser source. Since EVs of this size
are not visible with an optical microscope, we located EVs on the nanohole arrays by
mapping areas approximately (10 × 10) μm2 in size. Similarly to the Panc-MSC results
obtained with the 632.8 nm laser, the spectra corresponding to Panc-MSC (Figure 3-6A)
and BM-MSC (Figure 3-6B) EVs vary considerably, but common peaks within each data
set can still be identified. These common peaks are summarized in Table 3-2. Regarding
the SERS spectra of the Panc-MSC EVs (Figure 3-6A), protein peaks are identifiable at
813 cm-1 and 1151 cm-1, corresponding to C-C and C-N stretching, respectively.
Additionally, the peak at 1274 cm-1 belongs to amide III. Many amino acid peaks are
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located at 761 cm-1 (tryptophan), 873 cm-1 (hydroxyproline, tryptophan), 1206 cm-1
(hydroxyproline, tyrosine), and 1364 cm-1 (tryptophan). Lastly, the peak at 1334 cm-1 can
be attributed to CH2/CH3 twisting, bending, or wagging in collagen or nucleic acids.
Interestingly, there are far less peaks attributable to nucleic acids for the Panc-MSC EV
spectra obtained with the 785 nm laser compared to those obtained with the 632.8 nm laser,
and far more attributable to proteins and amino acids. The spectral differences between
Panc-MSC EVs acquired with the 632.8 nm and 785 nm lasers could be explained by EV
rupturing due to differences in laser energy, since the 632.8 nm excitation wavelength used
to collect the spectra in Figure 3-5 is higher in energy compared to the 785 nm excitation
wavelength used to collect the spectra in Figure 3-6A. Additionally, the spectra presented
in Figure 3-5 were gathered with longer acquisition times than the spectra presented in
Figure 3-6A, at 60 and 4 seconds, respectively. Although not specific to EVs, targeted
laser-induced cell lysis, or the breakdown of the cell membrane, has been demonstrated,
and a similar process could be unfolding here.[41,42] Since genetic material carried in EVs
is contained by a membrane typically decorated with surface proteins, we might expect to
see more protein signals compared to nucleic acid signals when the membrane is intact.
Regarding the SERS spectra of the BM-MSC EV (Figure 3-6B), many protein peaks are
also visible at 866 cm-1, 1158 cm-1, 1236 cm-1, 1265 cm-1, and 1658 cm-1. A few nucleic
acid peaks can be additionally seen at 803 cm-1 (uracil), 1480 cm-1 (guanine and adenine),
and 1612 cm-1 (cytosine). A lipid peak can also be found at 1077 cm-1, corresponding to a
C-C/C-O stretch.
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Figure 3-6: SERS spectra of (A) Panc-MSC EVs and (B) BM-MSC EVs acquired with
a 785 nm laser, where individual spectra are represented by lighter lines, average
spectra are represented by darker lines, and common spectral peaks are highlighted
in yellow.
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Table 3-2: Assignments of common peaks shared among BM-MSC and Panc-MSC
EV spectra from Figure 3-6.
Peak (cm-1)

BM

761
803

Ref. Peak (cm-1)

Ref.

Ring breathing in tryptophan

760

[38]

Ring breathing mode in uracil

802

[38]

Panc Presumed Origin
x

x

813

x

C-C stretch in collagen

813

[38]

836

x

Deformative vibrations of

838

[38]

C-C stretch in collagen

868

[39]

amine groups
866

x

873

x

Hydroxyproline, tryptophan

873

[38]

920

x

C-C stretch of proline

920

[38]

ring/glucose/lactic acid;
collagen assignment
998

x

C-O in ribose, C-C

996

[29,38]

1061

x

C-C in-plane bending; C-N

1053

[38]

C-C or C-O stretch in lipids

1078

[43]

C-N stretch in proteins

1152

[38,43]

C-C/C-N stretch in proteins

1158

[38]

Hydroxyproline, tyrosine

1206

[38]

stretching
1077

x

1151
1158

x
x

1206

x

(collagen assignment)
1236

x

Amide III

1235

[38]

1265

x

Amide III (collagen

1265

[43]

assignment)
1274

x

Amide III

1275

[38]

1334

x

CH2CH3 twisting and wagging

1335

[38,43]

Tryptophan

1365

[38]

in collagen and nucleic acids
1364

x

1400

x

N-H in-plane deformation

1400

[38]

1480

x

Ring breathing mode in

1485

[38]

guanine and adenine
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Peak (cm-1)

BM

Panc Presumed Origin

Ref. Peak (cm-1)

Ref.

1500

x

N-H bending

1506

[38]

1528

x

In-plane vibrations of -C=C-

1528

[40]

1612

x

Cytosine (NH2)

1610

[38]

1658

x

Amide I (α-helix)

1658

[38]

3.3.3

Statistical Analysis and Machine Learning

PCA was employed to reduce the dimensionality of the spectral data sets and to determine
the main compositional differences between the Panc-MSC and BM-MSC EVs. With
respect to the spectra presented in Figure 3-6, the first principal component (PC1) that
explains 50.7 % of variance corresponds to a protein peak at 1236 cm-1, which belongs to
amide III. The second principal component (PC2) that explains 15.5 % of variance
corresponds to an amino acid peak at 761 cm-1, which corresponds to tryptophan. However,
plotting PC1 versus PC2 reveals a large overlap in data between the two groups, limiting
the ability to separate the two EV types (Figure 3-7A). We additionally plotted PC1 versus
the third principal component (PC3), which accounts for 7.7 % of variance and corresponds
to a peak at 1528 cm-1 (in-plane -C=C- vibrations). In the second score plot, both data sets
are clustered more tightly compared to the first score plot, as evidenced by the smaller
confidence ellipses surrounding the former compared to the latter (Figure 3-7B). However,
there was still a great amount of overlap between the two ellipses, and we could only
classify the two EV groups with 82 % accuracy, 74 % sensitivity, and 84 % specificity.
It is not uncommon for PCA to perform poorly in terms of classification tasks since PCA
ignores class labels while attempting to maximize variance, and often PCA is used in
conjugation with other classification techniques to improve class separability.[44] To
mitigate this problem, we used the PC scores as classifiers in various machine learning
algorithms. Machine learning is a powerful and automatized technique that can be used to
make predictions about data without being explicitly programmed for these tasks. Treating
spectral data sets with PCA is favored when exploring classification techniques by machine
learning since smaller data sets are less computationally demanding for machine learning
algorithms, and therefore faster. Furthermore, feeding raw spectral data to a machine
learning algorithm can lead to overfitting due to the high dimensionality of the data.[45]
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Machine learning algorithms in conjunction with the PCA data obtained were thus explored
to increase class separation between the BM- and Panc-MSC EV spectral data as well as
classification accuracy.
Five different machine learning algorithms were employed: random forest (RF), SVM,
Naïve Bayes (NB), CN2 induction (CN2), and logistic regression (LR). RF is a technique
that includes an ensemble of decision trees, in which data are modeled in hierarchical
structures by a series of if/else statements.[46,47] SVM creates an optimal separating line for
the classification of all the input data into different classes, while NB is a statistical method
that computes the probability of an input’s relevance to a pre-defined class.[47] In rule
induction systems such as CN2, rules are created that fit the example cases, and solutions
are found by linking rules to known facts (i.e., the data set).[48] Lastly, LR calculates the
probability of class membership based on the sigmoid or logistic function.[49] Each model
was tested using LOOCV to minimize bias that could occur when training with a small
sample size. In the LOOCV procedure, one spectrum is held as a test sample while the
remaining 43 spectra are used to train the model, until each spectrum has been used as a
test sample once.
By visualizing the output scores, we observed that RF could not significantly separate the
two groups of EVs, while NB and LR performed the best in terms of class separation
(Figure 3-7C). To further assess the models, we plotted ROC curves and determined
AUCS. While all five models had high AUC values, NB, RF, and LR outperformed CN2
and SVM with AUC values of 0.901, 0.921, and 0.926, respectively, compared to 0.866
and 0.891 (Figure 3-7D). Since AUC values are quite close together, it is necessary to also
compare the models in terms of classification accuracy, sensitivity, and specificity (Table
3-3). CN2 had an unfavorable accuracy of 80 %, which was even lower than the accuracy
achieved using PCA only. SVM, RF, and NB performed marginally better than PCA only
with accuracies of 84 % each. LR was able to achieve a high accuracy of 89 %, as well as
a high sensitivity and specificity of 89 % and 88 %, respectively. While all five machine
learning algorithms performed well in terms of differentiating the Panc- and BM-MSC
EVs, LR is the most favorable approach for this data set, considering the high AUC,
accuracy, sensitivity, and specificity achieved compared to the four other algorithms.
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Figure 3-7: PCA score plots of Panc-MSC and BM-MSC clusters constructed with
(A) the first and second PCs and (B) the first and third PCs, where one data point
corresponds to one SERS spectrum. (C) Comparison of final output scores of data
given by PCA only (PC1 vs. PC3) and five machine learning algorithms, where one
data point corresponds to one SERS spectrum. (D) ROC curves comparing various
machine learning algorithms.

105

Table 3-3: Comparison of abilities of PCA and various machine learning algorithms
to discriminate BM-MSC and Panc-MSC EVs based on SERS spectra.
Model

Sensitivity

Specificity

Accuracy

PCA Only (PC1 vs. PC3)

74 %

84 %

82 %

Logistic Regression

89 %

88 %

89 %

Support Vector Machine

89 %

80 %

84 %

Random Forest

84 %

84 %

84 %

Naïve Bayes

95 %

76 %

84 %

CN2 Rule Induction

79 %

80 %

80 %

In terms of differentiating MSC-derived EVs from different sources, our model works
comparatively well with respect to other published studies, such as Gualerzi et al., who
achieved a classification accuracy of 93.7 %.[29] Although this accuracy is higher than that
achieved by our PCA-LR model, it is important to note that the spectra collected by
Gualerzi et al. had to undergo significant treatment prior to data analysis to remove
autofluorescence and background induced by their 532 nm laser. The use of a SERS
platform and a lower energy excitation wavelength (i.e., 785 nm) usually removes the need
for significant data treatment for better peak resolution, as demonstrated by the spectra we
obtained in this study (Figure 3-6) and highly simplifies the data analysis.

3.4 Conclusions
Plasmonically active nanohole arrays were used to trap single EVs isolated from Panc- and
BM-MSCs, which were subsequently analyzed by SERS. Although the nanohole arrays are
plasmonically active in the red and near-infrared wavelength regions, we determined that
the near-infrared (785 nm) laser was the most suitable for probing these biological samples.
By irradiating both Panc-MSC and BM-MSC EVs with the 785 nm laser, we found that
the SERS spectra for both groups contained predominantly protein peaks, as we would
expect to find on EV membrane surfaces, as well as some nucleic acid peaks. PCA was
employed to determine the main compositional differences between these two EV sources.
We determined that the peaks responsible for the most variance were located at 1236 cm1

, corresponding to amide III, 761 cm-1, belonging to tryptophan, and 1528 cm-1,
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corresponding to in-plane -C=C- vibrations. PC scores were then used as simple classifiers
in training machine learning algorithms to separate the Panc- and BM-MSC EVs. Using
simpler classifiers instead of the entire spectral data lowers the computational demand and
time required to complete this classification task. With a logistic regression machine
learning algorithm, we were able to distinguish between the two EV types with 89 %
accuracy, 89 % sensitivity, and 88 % specificity. In future work, we would like to challenge
these platforms with cancer-derived EVs to explore their feasibility as a tool in disease
detection and diagnosis.
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Chapter 4

4

Characterization of Ovarian Cancer-Derived
Extracellular Vesicles by Surface-Enhanced Raman
Spectroscopy

A version of this work has been published in the journal Analyst: Ćulum, N. M.; Cooper,
T. T.; Lajoie, G. A.; Dayarathna, T.; Pasternak, S. H.; Liu, J.; Fu, Y.; Postovit, L.-M.;
Lagugné-Labarthet, F. Characterization of Ovarian Cancer-Derived Extracellular Vesicles
Derived by Surface Enhanced Raman Spectroscopy. Analyst 2021, Accepted manuscript,
DOI: 10.1039/d1an01586a. This chapter has been reproduced with permission from the
Royal Society of Chemistry.
Ovarian cancer is the most lethal gynecological malignancy, owing to the fact that most
cases are diagnosed at a late stage. To improve prognosis and reduce mortality, we must
develop methods for the early diagnosis of ovarian cancer. A step towards early and noninvasive cancer diagnosis is through the utilization of EVs, which can be thought of as
nanoscale cancer biomarkers. In this chapter, the gold nanohole arrays presented in Chapter
3 are again used for the capture of EVs, this time from ovarian cancer (OvCa) cells, and
subsequent characterization by SERS. Investigated in this chapter are EVs isolated from
two established OvCa cell lines (OV-90 and OVCAR3), two primary OvCa cell lines
(EOC6 and EOC18), and one human immortalized ovarian surface epithelial cell line
(hIOSE) by SERS. The main compositional differences among these groups are identified
by PCA and machine learning is further employed to discriminate the groups with high
accuracy, sensitivity, and specificity.

4.1 Introduction
In 2021, ovarian cancer is estimated to be the fifth most lethal cancer in the United States
and the most lethal gynecological malignancy with 13 770 projected deaths.[1] The 5-year
survival rate for women diagnosed with ovarian cancer is 47 %.[2,3] However, ovarian
cancer usually presents at a late stage when the 5-year relative survival rate is 27 %, and
few cases are diagnosed when the tumor is localized with a 5-year relative survival rate of
92 %.[4] The high mortality rate of ovarian cancer is due to the diagnostic delay arising
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from the lack of early disease warning signs as well as the lack of early ovarian cancer
screening options.[3] There is a need for the development of non-invasive approaches for
the diagnosis of ovarian cancer, particularly at the early stage, which can be achieved by
the characterization of EVs and the analysis of their biomarkers.
Cancer-derived EVs and their functions were introduced in Section 1.2.2. Briefly, EVs are
involved in physio-pathological activities including cancer progression by mediating
crosstalk between tumor and stromal cells.[5,6] Cancer cells have additionally been
associated with an increase in EV production in comparison to normal cells, which could
be related to the specific conditions of the tumor microenvironment.[5] Since EVs carry
complex biological information from their parent cells, they are particularly interesting in
cancer research as they can be exploited as cancer biomarkers.[7,8] SERS, as utilized in
Chapter 3, is a promising technique for EV detection and characterization.[9] SERS analysis
of cancer-derived EVs has been greatly explored, particularly in breast,[10-16] lung, [17-23] and
pancreatic cancer.[24-26] Some studies have explored the SERS characterization of OvCaderived EVs,[27-30] but analysis has generally been less thorough compared to the other
cancer-derived EVs listed.
Early work in SERS characterization of OvCa EVs dates back to 2014, in which simple
AuNPs were utilized to analyze EVs from cell line A2780 grown in normoxic (normal O2)
and hypoxic (1 % O2) conditions.[27] However, with principal component analysis (PCA)
followed by discriminant function analysis, the two EV types could be only be
differentiated with 57.1 % sensitivity and 53.8 % specificity, and accuracy was not
reported. One year later, a silver film-coated plasmonic nanobowl substrate fabricated by
soft lithography on flexible polydimethylsiloxane was proposed for SERS analysis of EVs
isolated from the SKOV-3 cell line.[29] The authors did not evaluate the diagnostic potential
of the substrate since the purpose of the study was to compare EV purity from different
isolation methods. In 2017, a more selective approach using a thiolated peptide ligand for
the capture of EVs from SKOV-3 cells was reported.[28] The ligand was also bound to silver
NPs by a thiol-metallic bond for SERS analysis. While the authors were able to
demonstrate the targeted detection of OvCa EVs, they did not perform statistical analysis
to evaluate the diagnostic potential of the probe, and so accuracy, sensitivity, and
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specificity were not reported. Most recently in 2020, a simple plasmonic scaffold
consisting of a cysteamine-treated microscale biosilicate substrate embedded with AgNPs
was introduced for SERS analysis of EVs.[30] The authors investigated OvCa EVs derived
from SKOV-3 cells as well as from patients with ovarian and endometrial cancer. With
PCA-LDA, cancer could be diagnosed with 99.4 % accuracy, 100 % sensitivity, and 99.2
% specificity. However, the authors warned that these numbers must be interpreted with
caution given the small sample size used in analysis that could lead to biased results.
As evidenced by these four studies, most OvCa EVs analyzed by SERS are derived from
the SKOV-3 cell line. For this work, we sought to characterize EVs derived from OVCAR3
and OV-90 cells, which are well-established model systems for epithelial ovarian
adenocarcinomas. Given that most (90 %) malignant ovarian tumors are epithelial in origin,
and of these cancers, 70 % present as high-grade serous and < 5 % present as low-grade
serous,[4] we also chose to characterize EVs from high-grade serous (EOC6) and low-grade
serous (EOC18) primary cell lines. These four cell lines were compared to EVs derived
from a non-malignant human immortalized ovarian surface epithelial (hIOSE) cell line as
a control. As a SERS substrate, we again employed gold nanohole arrays fabricated by
EBL that we have extensively reported and characterized in past work. [31][32] Herein, we
report SERS spectra of the five aforementioned cell lines and were able to discriminate
their spectral signals by PCA and logistic regression with extremely high accuracy,
sensitivity, and specificity of approximately 99 % each.

4.2 Methods
4.2.1

Cell Culture

OV-90 (ATCC® CRL-11732) and NIH:OVCAR3 (ATCC® HTB-161) were obtained
from the ATCC. Human immortalized surface epithelial cells hIOSE (OSE364) were
obtained from the Canadian Ovarian Tissue Bank at the BC Cancer Agency. Primary cell
lines EOC6 and EOC18 were isolated from the ascites of patients with high-grade and lowgrade serous ovarian cancer, respectively. All cell lines, except OVCAR3, were maintained
in M199+MCDB105 supplemented with 5 – 15% FBS. NIH:OVCAR3 cells were cultured
in RPMI-1640 supplemented with 20 % FBS and 5 µg/mL insulin. Media was exchanged
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with serum-free media for 20 – 30 hours to generate conditioned media (CM) for EV
purification. All work involving the use of patient samples (cell lines, plasma, and ascites)
was approved by the Health Research Ethics Board of the Alberta Cancer Committee.

4.2.2

EV Isolation

OvCa CM samples were first centrifuged at 200 – 300 × g at 4 °C to pellet cells.
Supernatants (except CM) were diluted 1:10 in PBS and centrifuged at 3000 × g for 20
minutes at 4 °C to remove cell debris. To remove large membrane fragments, supernatants
were spun at 10 000 × g for an additional 20 minutes at 4 °C. Lastly, supernatants were
ultracentrifuged at 120 000 – 140 000 × g (SW-28 rotor) for 2 hours at 4 °C to pellet EVs
on an Optima L-100 XP ultracentrifuge (Beckman Coulter). The supernatant was removed
and EVs were resuspended in 100 – 300 µL of PBS and stored at -80 °C until further use.

4.2.3

EV Protein Extraction and Digestion

To prepare CM for proteomic analysis, ~ 30 µg of EVs were lyophilized to dryness and
reconstituted in 8 M urea, 50 mM ammonium bicarbonate (ABC), 10 mM dithiothreitol
(DTT), and 2 % SDS lysis buffer. Proteins were sonicated at 10 × 0.5 s pulses (Level 1)
with a probe sonicator (Fisher Scientific, Waltham, MA), reduced in 10 mM DTT for 30
minutes at room temperature (RT), alkylated in 100 mM iodoacetamide for 30 minutes at
RT in the dark, and precipitated in chloroform/methanol.[33] On-pellet in-solution protein
digestion was performed in 100 µL of 50 mM ABC (pH 8) by adding 1/50 Trypsin/Lys-C
(Promega) to digest EV proteins. EV proteins were incubated at 37 °C overnight (~ 20 h)
in a ThermoMixer C (Eppendorf) at 900 rpm before acidifying to pH 3 – 4 with 10 %
formic acid (FA). Salts and detergents were removed from peptide samples using C18
stagetips made in-house. Briefly, 10 layers were stacked into 200 µL pipette tips and rinsed
with ice-cold methanol. Stagetips were conditioned with solution A (80/20/0.1 %;
acetonitrile (ACN)/water/trifluoroacetic acid (TFA)), followed by solution B (5/95/0.1 %;
ACN/water/TFA) prior to loading ~ 20 µg of peptides resuspended in solution B. Duplicate
washes were performed with solution B prior to elution of peptides using solution C
(80/20/0.1 %; ACN/water/FA) and final elution using a 50/50 mixture of ACN/0.1 % FA.
Peptides were centrifuged at 45 ⁰C under vacuum and resuspended in 0.1 % FA prior to
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quantification by the bicinchonic acid assay (BCA) and injection into the mass
spectrometer.

4.2.4

Ultraperformance Liquid Chromatography Coupled to
Tandem Mass Spectrometry (UPLC-MS/MS)

Peptides were analyzed using an ACQUITY UPLC M-class system (Waters) connected to
a Q ExactiveTM Plus mass spectrometer (Thermo Scientific) using a nonlinear gradient.
Buffer A consisted of water/0.1 % FA and buffer B consisted of ACN/0.1 % FA. Peptides
(~ 1 µg estimated by BCA) were initially loaded onto an ACQUITY UPLC M-Class
Symmetry C18 Trap Column (100 Å, 5 µm, 180 µm × 20 mm) and trapped for 5 minutes
at a flow rate of 5 µL/min at 99 % A/1 % B. Peptides were separated on an ACQUITY
UPLC M-Class Peptide BEH C18 Column (130 Å, 1.7 µm, 75 µm × 250 mm) operating at
a flow rate of 300 nL/min at 35 °C using a non-linear gradient consisting of 1 – 10 % B,
10 – 20 % B, 20 – 30 % B, 30 – 40 % B, 40 – 50 % B, 60 – 70 % B, and 80 – 90 % B for
10 minute intervals before cyclic washing between 5 – 95 % B, equaling 140 minute
gradient total. Settings for data acquisition on the Q ExactiveTM Plus are outlined in Table
4-1.
Table 4-1: Parameters for Q ExactiveTM Plus.
Parameter

Parameter Setting

Orbitrap Resolution (MS1)

7 × 104

Mass Range

400 – 1500 m/z

MS1 Injection Time

200 ms

MS1 Automatic Gain Control (AGC) Target

3 × 106 ions/cycle

Lock Mass

445.120025 m/z

MS2 Detection

Fourier Transform

MS2 Resolution

1.75 × 104

MS2 AGC Target

2 × 105 ions/cycle

MS2 Injection Time

50 ms

Loop Count

12

Isolation Width

1.2 m/z
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Parameter

Parameter Setting

Isolation Offset

0.5 m/z

MS2 Activation

Higher-energy C-trap dissociation

Normalized Collision Energy

25 %

Dynamic Exclusion

12

Minimum AGC Target

2 × 103 ions/cycle

MS2 Intensity Threshold

8 × 104

Exclusion Duration

30 s

Charge Exclusion

Unassigned, 1, 8, > 8

Polarity

Positive

4.2.5

UPLC-MS/MS Data Analysis

MS raw files were searched with de novo peptide sequencing software PEAKS (version
10.5) using the Human Uniprot database (reviewed only, updated November 2020). Missed
cleavages were set to 5 and I = L. Cysteine carbamidomethylation was set as a fixed
modification. Oxidation (M), N-terminal acetylation (protein), and deamidation (NQ) were
set as variable modifications (maximum number of modifications per peptide = 7) and all
other settings were left as default. Precursor mass deviation was left at 20 ppm and 4.5 ppm
for first and main search, respectively. Fragment mass deviation was left at 20 ppm. Protein
and peptide false discovery rate was set to 0.01 (1 %) and the decoy database was set to
revert. Proteomic data analysis and visualization was performed in a Python 3+
environment, albeit comparison to Vesiclepedia databases was performed using the opensource FunRich (version 3.1.3) software.

4.2.6

nFC Measurements

OvCa EVs were analyzed for the number of microparticles/mL and EV size distribution by
nanoscale flow cytometry (nFC). Serial injections (2, 5, 10, or 20 mL) of each concentrate
were diluted to 300 mL with 0.22 mm-filtered PBS within low-attachment 96-well plates
at RT. EVs were enumerated in duplicate on the Apogee A60 nanoscale flow cytometer
with autosampler, capable of EV resolution between 150 and 1000 nm.[34] 130 μL of diluted
CM was injected and analyzed at 1.5 μL/min for 1 minute. The size of secreted
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microparticles was estimated using silica beads ranging 110 – 1300 nm using properties of
large-angle light scatter and small-angle light scatter. Silica beads provide a refractive
index (k = 1.42) that is closer to cells (k = 1.35 – 1.39) than commonly used polystyrene
beads (k = 1.59).

4.2.7

Nanohole Array Fabrication

The nanohole arrays presented in this chapter were fabricated by EBL following the same
protocol outlined in Section 3.2.1, established by Kaufman et al.[31]

4.2.8

SERS Measurements

Concentrated EV samples were diluted 1:20 with Milli-Q water. 10 – 20 μL of dilute EV
samples were drop-cast onto nanohole arrays and subsequently removed using cohesive
properties allowed by a Kimwipe absorbent paper (Kimberly-Clark Inc.). The edge of the
absorbent paper was placed on the corner of the solution droplet, allowing for solution
removal via capillary action. EV solutions were allowed to dry for 15 – 30 minutes prior
to SERS measurements. EVs were located in nanoholes by SERS mapping, and spectra
were extracted from these maps. SERS spectra were acquired with an XploRATM PLUS
spectrometer (Horiba Scientific) using a 785 nm excitation laser source, 600 grooves/mm
grating, 100 × objective (N.A. = 0.9), and 100 μm pinhole. Laser power was set to 5 mW
with an acquisition time of 4 seconds per spectrum.

4.2.9

Statistical Analysis and Machine Learning

PCA and machine learning were completed with Orange software (version 3.28.1). All
SERS spectra were standardized to μ = 0, σ2 = 1 prior to PCA, and outliers were removed
by the Local Outlier Factor method with contamination set to 10 %. Retained spectra were
analyzed by PCA and the first 25 PCs were selected to explain 97 % of variance among
spectra. The first 25 PCs were used as input data in a logistic regression-based machine
learning algorithm. Models were trained and tested using 5-fold CV.
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4.3 Results and Discussion
4.3.1

Validation of EV Size and Proteomic Cargo

Size quantification of EVs by nFC and proteomic analysis by UPLC-MS/MS was
conducted to validate the enrichment of EVs by ultracentrifugation (UC) from CM
generated by four OvCa cell lines and one normal control cell line (Figure 4-1). Amongst
several methods available for EV purification,[35-38] this study considered UC as an optimal
balance between EV yield and purity. UC provides a heterogenous mixture of EVs which
includes both microvesicles and exosomes. Therefore, the use of the term EV throughout
this study is in accordance with the ISEV.[39]

Figure 4-1: Schematic illustration of nFC and UPLC-MS/MS analysis of OvCa EVs.
The size distribution of EVs was verified by nFC (Figure 4-2A), estimated by small-angle
light scatter measurements. In support of previous studies,[34] we demonstrate a near-linear
detection of particles as the volume of sample analyzed was diminished, indicating
acceptable EV purity (Figure 4-2B). The majority of EVs detected were estimated to be
less than 240 nm in diameter (Figure 4-2C), which is consistent with the size of
microvesicles and exosomes.[40] However, the resolution of exosomes less than 100 nm in
diameter from background noise was unattainable based on the properties of the cytometer
used in this study, but subsequent proteomic analysis was able to verify the presence of EV
markers in each OvCa sample.
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Figure 4-2: (A) Representative flow cytometry plots (top) and corresponding size
distributions (bottoms) of EV samples from OV-90 (left) and hIOSE (middle) cell
lines, as well as conditioned media (right). (B) nFC results revealed a near-linear
decrease in the number of particles as the volume of sample analyzed diminished. The
horizontal dashed line indicates the mean particle number when an equal volume of
background media (PBS) was analyzed. (C) Size distribution of EVs.
UPLC-MS/MS is a powerful tool to detect and quantify proteomic cargo within EVs
(Figure 4-3A-B). In total, we identified over 3000 proteins in EVs generated by all five
cell lines. However, unique proteomic cargo was detected among each. Specifically, 1014
peptides were shared by EVs from all five cell lines, whereas 138, 410, 115, 304, and 145
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peptides were unique to hIOSE, OV-90, OVCAR3, EOC6, and EOC18, respectively
(Figure 4-3C). Distinct proteomic fingerprints were identified by PCA, where PC1 and
PC2 scores correspond to tetraspanin-8 (TSPAN8) and histone H2A type 1 (HIST1H2A),
respectively (Figure 4-3D). EVs isolated from OVCAR3, OV-90, and EOC6 each
demonstrate a distinguishing proteome compared to EVs isolated from hIOSE and EOC18.
A high PC1 score indicates the presence of TSPAN8 in EVs isolated from OV-90 and
EOC6, while a high PC2 score indicates the presence of HIST1H2A in EVs isolated from
OVCAR-3 and OV-90. EVs isolated from hIOSE and EOC18 are both associated with low
PC1 and PC2 scores, indicating a low presence of TSPAN8 and HIST1H2A in these EVs.
Furthermore, EVs from hIOSE and EOC18 are clustered closely to one another on the score
plot, indicating that there is a high similarity between normal EVs and low-grade OvCa
EVs, as expected. OvCa proteomes identified here were compared with those available in
the Vesiclepedia database filtered for OvCa cell lines (Figure 4-3E). Of 6202 proteins with
OvCa EV proteomes in this database, 1429 were shared with EV proteomes identified
within our samples. Classical EV markers (e.g., CD9/81/63) were also confidently detected
in EVs isolated from all five cell lines in addition to 22 core exosome proteins recently
identified by UPLC-MS/MS (Figure 4-3F).[41] Collectively, our nFC and proteomic data
support UC as a suitable method for the enrichment of EVs for downstream SERS analysis.
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Figure 4-3: (A) Number of MS1 and MS2 scans for duplicate injections of each EV
sample. (B) Number of peptides identified by de novo sequencing, which led to
confident protein identification with false discovery rate (p < 0.01). (C) Venn diagram
highlighting the distinct proteomics cargo contained within EVs from various OvCa
cell lines, leading to distinct proteomic “fingerprints” as demonstrated by (D) PCA.
(E) Overlap of OvCa EV proteomes with Vesiclepedia database filtered for OvCa. (F)
Heat map indicating that classical EV markers (e.g., CD9/81/63) were confidently
identified in all OvCa EV samples.
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4.3.2

EV Characterization by SERS

Gold nanohole arrays of different shapes (squares, triangles) and sizes (500 nm, 1000 nm)
were fabricated by EBL as plasmonic substrates for the capture and SERS analysis of
normal and OvCa-derived EVs. SEM images of these arrays and the characterization of
their LSPRs can be found in Chapter 3. EVs isolated from the hIOSE cell line serve as a
control group (Figure 4-4A). The majority of peaks found in hIOSE EVs are attributed to
proteins and amino acids, which include the peaks at 755 cm-1 (tryptophan), 818 cm-1 (CC stretching in collagen), 935 cm-1 (proline, valine, protein backbone), 1029 cm-1
(phenylalanine), 1303 cm-1 (collagen, amide III), and 1545 cm-1 (amide II).[42,43] Several
nucleic acid peaks are located at 724 cm-1 (adenine), 787 cm-1 (cytosine, uracil, thymine),
1185 cm-1 (cytosine, guanine, adenine), 1356 cm-1 (guanine), and 1482 cm-1 (guanine,
adenine).[42,43] Lipid and carbohydrate peaks can be found at 1254 cm-1 and 865 cm-1,
respectively.[42,43] A complete list of SERS peaks of hIOSE EVs are summarized in Table
4-2.
Table 4-2: Summary of peak assignments of hIOSE EVs, as highlighted in Figure 44A.
Peak (cm-1)

Presumed Origin

Ref. Peak (cm-1)

Ref.

630

Glycerol

630

[42,43]

692

Ring deformation

686

[43]

724

Ring breathing mode of adenine

725

[42,43]

755

Symmetric breathing of tryptophan

755

[43]

787

Ring breathing mode of cytosine, uracil,

786

[42,43]

thymine
818

C-C stretching in collagen

817

[42,43]

837

Deformative vibrations of amine groups

838

[42,43]

865

C-C stretching or C-O-C skeletal mode in

868

[42,43]

935

[42,43]

963

[42,43]

carbohydrates
935

C-C stretching mode of proline, valine,
and protein backbone (α-helix); glycogen

961

Unassigned in protein assignments
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Peak (cm-1)

Presumed Origin

Ref. Peak (cm-1)

Ref.

1029

Phenylalanine of collagen

1030

[43]

1090

Symmetric phosphate stretching

1090

[42,43]

vibrations
1185

Cytosine, guanine, adenine

1180 – 1184

[42,43]

1254

Lipids

1255

[42,43]

1303

CH2/CH3 twisting, wagging, or bending

1302

[42,43]

mode of lipid/collagen; amide III
1356

Guanine

1355, 1357

[42,43]

1404

C-H deformation

1404

[42]

1455

Deoxyribose; CH2 scissoring of proteins

1455

[43]

and lipids
1482

Ring breathing mode of guanine, adenine

1485

[42,43]

1545

Amide II

1544

[42]

EVs from two established OvCa cell lines, OV-90 and OVCAR3, serve as cancer models
(Figure 4-4B). SERS spectra of EVs from both OV-90 and OVCAR3 are dominated by
protein and amino acid peaks. For OV-90 EVs, these peaks are located at 755 cm-1
(tryptophan), 908 cm-1 (tyrosine), 1008 cm-1 (phenylalanine), 1036 cm-1 (phenylalanine),
1151 cm-1 (C-N stretch), 1274 cm-1 (amide III), 1335 cm-1 (collagen, amide III), and 1533
cm-1 (amide II).[42,43] For OVCAR3 EVs, the protein and amino acid peaks are found at 741
cm-1 (tryptophan), 818 cm-1 (collagen), 935 cm-1 (proline, valine, protein backbone), 956
cm-1 (CH3 stretching), 1055 cm-1 (C-O, C-N stretching), 1176 cm-1 (tyrosine), 1197 cm-1
(tryptophan), 1226 cm-1 (amide III), and 1584 cm-1 (phenylalanine).[42,43] Second most
abundant for OV-90 and OVCAR3 EVs are nucleic acid peaks. For OV-90 EVs, these
nucleic acid peaks are located at 675 cm-1 (guanine), 782 cm-1 (thymine, cytosine, uracil),
822 cm-1 (phosphodiester), 1186 cm-1 (cytosine, guanine, adenine), and 1201 cm-1 (nucleic
acids and phosphates).[42,43] For OVCAR3 EVs, the nucleic acid peaks are located at 675
cm-1 (guanine), 724 cm-1 (adenine), 1176 cm-1 (cytosine, guanine), 1376 cm-1 (adenine),
and 1483 cm-1 (guanine, adenine).[42,43] Carbohydrate peaks in the OV-90 SERS spectrum
are found at 943 cm-1, 1118 cm-1, and 1370 cm-1, and in the OVCAR3 SERS spectrum are
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found at 848 cm-1, 929 cm-1, and 994 cm-1.[42,43] Lastly, OV-90 lipid peaks are located at
714 cm-1, 719 cm-1, and 1467 cm-1, while an OVCAR3 lipid peak is found at 1299 cm1 [42,43]

.

The complete list of spectral peaks for OV-90 and OVCAR3 EVs are summarized

in Table 4-3 and Table 4-4, respectively.
Table 4-3: Summary of peak assignments of OV-90 EVs, as highlighted in Figure 44B.
Peak (cm-1)

Presumed Origin

Ref. Peak (cm-1)

Ref.

632

Glycerol

630 *

[42,43]

675

Ring breathing mode in guanine

678

[42,43]

714

C-N (membrane phospholipid head);

717

[43]

719

[42,43]

adenine
719

C-N (membrane phospholipid head),
symmetric stretch vibration of choline
group N+(CH3)3; nucleotide

755

Symmetric breathing of tryptophan

755 *

[43]

782

Ring breathing in thymine, cytosine,

782

[42,43]

uracil
822

Phosphodiester

822

[42,43]

908

Tyrosine

906

[42]

943

Skeletal modes in polysaccharides

941

[42,43]

1008

Phenylalanine

1008

[42,43]

1036

C-H in-plane bending mode of

1036

[43]

phenylalanine
1118

Glucose

1117

[42,43]

1151

C-N stretching in proteins

1152

[42,43]

1186

Cytosine, guanine, adenine

1180 – 1184 *

[42,43]

1201

Nucleic acids and phosphates; aromatic

1200

[42,43]

C-O and C-N
1220

C=N=C stretching

1220

[42,43]

1274

Amide III

1275

[42,43]
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Peak (cm-1)

Presumed Origin

Ref. Peak (cm-1)

Ref.

1335

CH2/CH3 twisting and wagging in

1335

[42,43]

collagen and nucleic acids; C-N stretching
in amide III
1370

Saccharide band

1370

[42,43]

1403

C-H deformation

1404 *

[42]

1467

Lipids

1465

[42,43]

1533

Amide II

1542

[42]

* Also present in control (hIOSE) spectrum.
Table 4-4: Summary of peak assignments of OVCAR3 EVs, as highlighted in Figure
4-4B.
Peak (cm-1)

Presumed Origin

Ref. Peak (cm-1)

Ref.

675

Ring breathing mode in guanine

678

[42,43]

687

Ring deformation

686 *

[43]

724

Ring breathing mode of adenine

725 *

[42,43]

741

DNA, tryptophan

742

[42]

818

C-C stretching in collagen

817 *

[42,43]

848

C-O-C skeletal mode in carbohydrates

847

[42,43]

929

Carbohydrates

931

[42,43]

935

C-C stretching mode of proline, valine,

935 *

[42,43]

and protein backbone (α-helix); glycogen
956

CH3 stretching in proteins (α-helix)

951

[42,43]

994

C-O ribose, C-C

996

[42,43]

1055

C-O stretching, C-N stretching in proteins

1053

[42,43]

1176

C-H bending in tyrosine

1176

[42]

1197

Tryptophan ring breathing

1199

[42]

1226

Amide III (β-sheet)

1224

[42,43]

1299

Acyl chains, fatty acids

1298

[42,43]

1324

CH2/CH3 wagging mode in collagen and

1324

[42,43]

purine bases
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Peak (cm-1)

Presumed Origin

Ref. Peak (cm-1)

1346

Adenine and guanine; C-H deformation of 1344

Ref.
[43]

proteins
1376

Ring breathing mode of adenine

1376

[43]

1455

Deoxyribose; CH2 scissoring of proteins

1455 *

[43]

and lipids
1483

Ring breathing mode of guanine, adenine

1485 *

[42,43]

1529

-C=C- in-plane vibrations

1525

[42,43]

1584

C=C bending mode of phenylalanine

1583

[42,43]

* Also present in control (hIOSE) spectrum.
EVs from two primary OvCa cell lines, EOC6 and EOC18, were also probed as models of
high-grade and low-grade serous cancer, respectively (Figure 4-4C). Like the EVs from
the three aforementioned cell lines, the SERS spectra of EOC6 and EOC18 EVs are
dominated by protein and amino acid peaks. For EOC6 EVs, these peaks are located at 639
cm-1 (tyrosine), 939 cm-1 (C-C skeletal stretching), 1003 cm-1 (phenylalanine), 1159 cm-1
(C-C/C-N stretching), 1162 cm-1 (tyrosine), 1225 cm-1 (amide III), 1265 cm-1 (collagen,
phenylalanine), 1439 cm-1 (collagen), and 1558 cm-1 (tryptophan, tyrosine, amide II).[42,43]
For EOC18 EVs, protein and amino acid peaks are found at 756 cm-1 (tryptophan), 852 cm1

(proline, hydroxyproline, tyrosine), 935 cm-1 (proline, valine, protein backbone), 987 cm-

1

(phenylalanine), 1032 cm-1 (phenylalanine, proline), 1209 cm-1 (tryptophan,

phenylalanine), 1248 cm-1 (amide III), 1338 cm-1 (amide III), and 1362 cm-1
(tryptophan).[42,43] However, fewer nucleic acid peaks are located compared to OV-90 and
OVCAR3 EVs, which are found at 797 cm-1 (uracil) for EOC6 EVs and 677 cm-1 (guanine)
and 1577 cm-1 (guanine, adenine) for EOC18 EVs.[42,43] Lipid peaks for EOC6 EVs are
located at 736 cm-1, 775 cm-1, and 1367 cm-1, and in EOC18 EVs are found at 1166 cm-1,
1300 cm-1, 1466 cm-1.[42,43] Lastly, carbohydrate peaks of EOC6 EVs are present at 845 cm1

and 1023 cm-1, while one carbohydrate peak at 1425 cm-1 is present in the SERS spectra

of the EOC18 EVs.[42,43] The complete list of spectral peaks of the EOC6 and EOC18 EVs
are summarized in Table 4-5 and Table 4-6, respectively.
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Table 4-5: Summary of peak assignments of EOC6 EVs, as highlighted in Figure 44C.
Peak (cm-1)

Presumed Origin

Ref. Peak (cm-1)

Ref.

639

Tyrosine ring breathing

639

[42]

694

Ring deformation

686 *

[43]

736

Phosphatidylserine

733

[42,43]

775

Phosphatidylinositol

776

[42,43]

797

Ring breathing mode in uracil

802

[42,43]

845

C-O-C skeletal mode in carbohydrates

847

[42,43]

886

Ring deformation and symmetric C-N-C

886

[43]

stretching
939

C-C skeletal stretching in proteins

939

[43]

1003

C-C skeletal mode, phenylalanine

1003

[42,43]

1023

Glycogen

1023

[42,43]

1096

Phosphodioxy group (PO2- in nucleic

1096

[42,43]

acids)
1159

C-C/C-N stretching in proteins

1158

[42]

1162

Tyrosine

1163

[42]

1225

Amide III (β-sheet)

1224

[42,43]

1265

Amide III of collagen; C-C6H5 stretching

1265

[43]

1332

[42,43]

in phenylalanine
1332

C-C stretching in phenyls, C-O stretching,
C-H in-plane bending

1367

CH3 stretching in phospholipids

1367

[42,43]

1404

C-H deformation

1404 *

[42]

1439

CH2/CH3 deformation in collagen

1439

[42,43]

1520

-C=C- in-plane vibrations

1525

[42,43]

1558

Tryptophan, tyrosine, amide II

1558

[42,43]

* Also present in control (hIOSE) spectrum.
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Table 4-6: Summary of peak assignments of EOC18 EVs, as highlighted in Figure 44C.
Peak (cm-1)

Presumed Origin

Ref. Peak (cm-1)

Ref.

612

Cholesterol ester

614

[42,43]

648

Ring, cyclic deformation

649

[43]

677

Ring breathing in guanine

678

[42,43]

756

Symmetric breathing of tryptophan

755 *

[43]

835

Deformative vibrations of amine groups

838 *

[42,43]

852

Proline, hydroxyproline, tyrosine

852

[42,43]

935

C-C stretching mode of proline, valine,

935 *

[42,43]

991

[42]

and protein backbone (α-helix); glycogen
987

Phenylalanine

1032

CH2/CH3 bending modes of phenylalanine 1032

[42,43]

and proline of collagen, phospholipids
1076

Symmetric stretching of PO43-

1076

[42]

1166

Lipids

1168

[42,43]

1209

C-C6H5 stretching mode in tryptophan and 1209

[42,43]

phenylalanine
1248

Amide III

1248

[42]

1262

Ring breathing mode in thymine, adenine;

1263

[42,43]

=C-H bending in proteins
1300

CH2 twisting in lipids, fatty acids

1300

[42,43]

1338

Amide III

1338

[43]

1362

Tryptophan

1360

[42,43]

1386

CH3 band

1386

[42,43]

1425

Deoxyribose

1424

[42,43]

1466

Lipids

1465

[42,43]

1473

C=N stretching

1470

[42,43]

1577

Guanine, adenine

1578

[42]

* Also present in control (hIOSE) spectrum.
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Figure 4-4: Average SERS spectra of (A) ovarian epithelial cell line-derived EVs
(control), (B) established OvCa cell line-derived EVs, and (C) primary OvCa cell line-
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derived EVs. Average SERS spectra of hIOSE, OV-90, OVCAR3, EOC6, and EOC18
are comprised of 207, 123, 106, 166, and 156 spectra, respectively.

4.3.3

Spectral Analysis by PCA

Often, the first two PCs are used to compare different classes of samples as they contain
most of the information of the original data set. However, sometimes the first two PCs
alone are not enough to differentiate classes of samples.[44] In our case, the PC18 and PC25
scores best separated the EV types, although they account for a very small percentage of
the original data set (Figure 4-5A-C). These PCs were determined by the informative
projections feature in Orange software, which ranks attribute pairs by classification
accuracy. PC18 best differentiates the normal group from the cancer groups, where the
latter tends to be associated with more negative PC18 scores. (Figure 4-5D). PC25
interestingly best separates the cancer groups in terms of the severity of cancer, where
higher-grade cancers (e.g., EOC6, OVCAR3, OV-90) tend to be associated with more
positive PC25 scores.
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Figure 4-5: PC score plots comparing (A) normal (hIOSE) vs. cancer (OV-90,
OVCAR3) EVs, (B) normal vs. high-grade cancer (EOC6) EVs, (C) normal vs. lowgrade cancer (EOC18) EVs, and (D) all groups to highlight separation along PC18. In
(A) – (C), each point corresponds to one SERS spectrum while the points in (D)
correspond to the centroids of each group in (A) – (C).
PC loading spectra of PC18 and PC25 scores were compared to the average spectrum of
each EV type presented in Figure 4-4 to interpret which spectral peaks are responsible for
the most variance in the data set (Figure 4-6). PC18 is best described by protein
assignments at 728 cm-1 (tryptophan) and 1237 cm-1 (amide III), nucleic acid assignments
at 782 cm-1 (thymine, cytosine, uracil), 1180 cm-1 (cytosine, guanine), and 1483 cm-1
(guanine, adenine), and a carbohydrate peak at 942 cm-1 (polysaccharides) (Figure 4-6A,
Table 4-7). The more positive PC18 peaks at 782 cm-1, 1181 cm-1, and 1483 cm-1 tend to
be more associated with the normal EVs than the OvCa EVs (i.e., all three peaks are found
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in the hIOSE spectrum but not in each of the OvCa spectra). Interestingly, these three peaks
are all nucleic acid in origin. PC25 is best described by protein assignments at 743 cm-1
(tryptophan), 832 cm-1 (tyrosine), 973 cm-1 (CH3, CCH vibrations), and 1170 cm-1
(tyrosine), a carbohydrate peak at 940 cm-1 (polysaccharides), and a lipid peak at 1060 cm1

(ceramide) (Figure 4-6B, Table 4-8). More positive PC25 peaks located at 940 cm-1,

1060 cm-1, and 1170 cm-1 tend to be associated more with the high-grade cancer EVs
(EOC6) than the low-grade cancer EVs (EOC18). While PCA is a valuable tool to
determine how spectra differ from one another, the PC scores determined can also serve as
classifiers in machine learning algorithms to better differentiate classes of data.

Figure 4-6: Average SERS spectra of EVs derived from each cell type (also shown in
Figure 4-5) compared with (A) PC18 and (B) PC25 loading spectra. Key peaks (i.e.,
spectral peaks that best describe each PC) are highlighted with vertical dashed lines.
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Table 4-7: SERS peaks that best differentiate normal vs. cancer groups, as
highlighted in Figure 4-7A.
Peak (cm-1)

Presumed Origin

Ref. Peak (cm-1)

Ref.

728

Ring breathing of tryptophan

728

[42]

782

Thymine, cytosine, uracil ring breathing

782

[42,43]

modes
942

Skeletal modes of polysaccharides

941

[42,43]

1181

Cytosine, guanine

1180

[42,43]

1237

Amide III, CH2 wagging vibrations from

1237

[42,43]

1485

[42,43]

glycine backbone and proline side chains
1483

Guanine, adenine ring breathing modes

Table 4-8: SERS peaks that best differentiate low-grade vs. high-grade cancer groups,
as highlighted in Figure 4-7B.
Peak (cm-1)

Presumed Origin

Ref. Peak (cm-1)

Ref.

743

DNA, tryptophan

742

[42]

832

Asymmetric O-P-O stretching, tyrosine

831

[42,43]

940

Skeletal modes of polysaccharides

941

[42,43]

973

CH3, CCH vibrations in proteins

973

[42,43]

1060

C-C in-plane bending, C-N stretching,

1061

[42]

1170

[42,43]

ceramide
1170

4.3.4

C-H in-plane bending mode of tyrosine

Machine Learning for Ovarian Cancer Diagnosis

A logistic regression-based machine learning algorithm was used to classify normal and
OvCa EVs based on the first 25 PCs calculated. Several algorithms were tested and
compared based on the AUC values of their ROC curves (Figure 4-7). Logistic regression
was chosen for the high AUC obtained as well as extremely high accuracy, precision, and
recall, although some algorithms like SVM worked almost as well (Table 4-9). The
algorithm was trained and tested with 5-fold CV to reduce potential overfitting.
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Figure 4-7: ROC curves comparing six different machine learning algorithms: SVM,
logistic regression, random forest, kNN, Naïve Bayes, and CN2 rule inducer. The
upper left-most portion is zoomed in and highlighted in red (right).

Table 4-9: Comparison of accuracies, sensitivities, and specificities achieved with the
six machine learning algorithms shown in Figure 4-8.
Model

Accuracy

Precision

Recall

Logistic Regression

98.6 %

98.6 %

98.6 %

SVM

97.3 %

97.4 %

97.3 %

Random Forest

91.0 %

91.1 %

91.0 %

Naïve Bayes

86.5 %

88.4 %

86.5 %

kNN

86.5 %

87.1 %

86.5 %

CN2 Rule Inducer

77.4 %

77.4 %

77.4 %

Four groups of data were compared: (1) normal (hIOSE) EVs vs. established OvCa cell
line (OV-90, OVCAR3) EVs (Figure 4-8A), (2) normal EVs vs. high-grade OvCa (EOC6)
EVs (Figure 4-8B), (3) normal EVs vs. low-grade OvCa (EOC18) EVs (Figure 4-8C),
and (4) low-grade vs. high-grade OvCa EVs (Figure 4-8D). Heat maps shown in Figure
4-8 were created to visualize the machine learning output scores of each sample. A vast
majority of OvCa EVs were successfully classified as cancerous, as indicated by the red
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and dark orange bars in Figure 4-8A-C. Similarly, a majority of the EOC6 EVs were
successfully classified as high-grade, also indicated by the red and dark orange bars in
Figure 4-8D.
EVs isolated from hIOSE were compared to EVs isolated from OV-90, OVCAR3, and
EOC6 to determine the platform’s capability of correctly diagnosing OvCa. When the
established cell line EVs were used as training sets for the cancer group, 196 out of 198
OvCa EV samples were correctly identified as cancerous, while 199 out of 200 normal EV
samples were correctly identified as non-cancerous (Figure 4-8A), corresponding to 99.2
% classification accuracy, 99.0 % sensitivity, and 99.5 % specificity. When the EOC6 EVs
were used as a training set for a cancer group, 155 out of 157 OvCa samples were correctly
identified as cancerous, while 199 out of 200 normal EVs were again correctly classified
as non-cancerous (Figure 4-8B). The resulting classification accuracy was identical to the
normal vs. established OvCa cell line model at 99.2 %. The sensitivity dipped slightly to
98.7 %, but the specificity remained the same at 99.5 %.
EVs isolated from hIOSE were compared to EVs isolated from EOC18 to determine the
platform’s capability of correctly diagnosing low-grade OvCa, which can be more of a
challenge compared to high-grade OvCa since low-grade OvCa cells tend to more closely
resemble normal cells. With the EOC18 EVs as a training set for the cancer group, all 136
OvCa samples were correctly identified as cancerous, while 198 out of 200 normal EVs
were correctly classified as non-cancerous (Figure 4-8C). The 99.4 % accuracy achieved
here is comparable to the previous two models, suggesting we can successfully classify
both low-grade and high-grade OvCa samples with extremely high accuracy. Furthermore,
we were also able to achieve high sensitivity and specificity at 100 % and 99.0 %,
respectively.
EVs isolated from EOC6 and EOC18 were compared to determine the platform’s capability
of predicting whether an OvCa sample is high-grade or low-grade, since the grade of OvCa
can help predict the prognosis of the disease as well as how the cancer may respond to
treatment. 154 out of 157 EOC6 samples were correctly identified as high-grade, while all
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136 EOC18 samples were correctly identified as low-grade, corresponding to 99.0 %
accuracy, 98.1 % sensitivity, and a 100 % specificity (Figure 4-8D).

Figure 4-8: Heat maps (left) to visualize output scores of (A) normal vs. established
cancer cell line EVs, (B) normal vs. high-grade cancer EVs, (C) normal vs. low-grade
cancer EVs, and (D) low-grade vs. high-grade cancer EVs, with corresponding
confusion matrices (right). In the heat maps, each horizontal bar corresponds to one
SERS spectrum. Groups labeled on the left indicate the origin of the sample, while
the color of the bar indicates the algorithm’s prediction. In (A) – (C), a red or dark
orange color (output score > 0.5) corresponds to a cancer prediction and a yellow or
light orange color (output score < 0.5) corresponds to a normal prediction. In (D), a
red or dark orange color (output score > 0.5) corresponds to a high-grade cancer
prediction and a yellow or light orange color (output score < 0.5) corresponds to a
low-grade cancer prediction.
The accuracies, sensitivities, and specificities achieved with each of the four models
compared in Figure 4-8 is summarized in Table 4-10. The high accuracies presented here
indicate that this platform and methodology is not only promising in terms of ovarian
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cancer diagnosis, but also promising in determining the grade of disease. Since EVs are
found in bodily fluids such as urine, plasma, and saliva, this approach has a strong potential
for non-invasive ovarian cancer diagnosis.
Table 4-10: Comparison of accuracies, sensitivities, and specificities achieved with
each group compared in Figure 4-8.
Model

Accuracy

Sensitivity

Specificity

hIOSE vs. OV-90, OVCAR3

99.2 %

99.0 %

99.5 %

hIOSE vs. EOC6

99.2 %

98.7 %

99.5 %

hIOSE vs. EOC18

99.4 %

100 %

99.0 %

EOC18 vs. EOC6

99.0 %

98.1 %

100 %

4.4 Conclusion
In conclusion, we have presented plasmonic gold nanohole arrays for the capture of single
EVs which we subsequently characterized by SERS. To our knowledge, this is the first
time EVs from these five cell lines (OV-90, OVCAR3, EOC6, EOC18, and hIOSE) have
been characterized by SERS. We then were able to determine their main compositional
differences by PCA. We found that normal EVs could generally be differentiated from
OvCa EVs by the presence of peaks at 782 cm-1 (thymine, cytosine, uracil ring breathing
modes), 1181 cm-1 (cytosine, guanine), and 1483 cm-1 (guanine, adenine ring breathing
modes). Interestingly, high-grade cancer could also be predicted based on the presence of
peaks at 940 cm-1 (polysaccharides), 1060 cm-1 (C-C in-plane bending, C-N stretching,
ceramide), and 1170 cm-1 (tyrosine).
The PC scores calculated were then used as classifiers in a logistic regression-based
machine learning algorithm, which was able to differentiate normal EVs from the
established OvCa cell line EVs with 99.2 % accuracy, 99.0 % sensitivity, and 99.5 %
specificity. Normal EVs could also be discriminated from the high-grade primary cell line
EVs with 99.2 % accuracy, 98.7 % sensitivity, and 99.5 % specificity. Interestingly, we
were also able to differentiate the normal EVs from the low-grade primary cell line EVs
with 99.4 % accuracy, 100 % sensitivity, and 99.0 % specificity. Lastly, the low-grade and
high-grade primary cell line EVs could also be discriminated with 99.0 % accuracy, 98.1
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% sensitivity, and 100 % specificity. The diagnostic potential presented here is a great step
towards early, non-invasive, facile, and rapid ovarian cancer diagnosis. However, at this
stage in the study, the results are proof-of-concept; until clinical samples are obtained from
ovarian cancer patients and from healthy individuals, we cannot determine precisely how
the model will perform with new test data. Therefore, the next step in this study is to
challenge the platforms with EVs from clinical samples to determine the feasibility of using
this methodology in a clinical setting.
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Chapter 5

5

Conclusions and Outlook

As highlighted in the introduction of this thesis, EVs can generally be split into two groups
based on their cellular origins and applications: as cell-free therapeutic agents in
regenerative medicine, and as biomarkers for various diseases, including cancer. The main
research goal of this work was to fabricate SERS substrates for EV capture and
characterization, and EVs from each of the aforementioned groups were studied.
The first chapter of this thesis provided background information of EVs, including their
functions and importance, and established the research interest of EVs in both therapeutic
and diagnostic applications. Several standard methods for EV characterization were
reviewed in this chapter, encompassing both physical (e.g., Brownian motion-based and
microscopic techniques) and biochemical methods (e.g., MS-based and immunoassay
techniques). An overview of nanoplasmonic approaches was also introduced, including
SPR sensing, LSPR sensing, and SERS. Since SERS was the main technique implemented
for EV characterization in this thesis, it was discussed further in Chapter 2.
The second chapter of this thesis delved into the fundamentals of Raman spectroscopy and
provided background information of the types of spectral fingerprints that could be
expected for biological systems arising from biological macromolecules (i.e., proteins,
nucleic acids, lipids, and carbohydrates). The main limitation of Raman spectroscopy, low
sensitivity, was highlighted, and the need for SERS analysis was presented. In addition to
providing the physical background behind SERS sensing, several SERS studies of EVs
conducted in recent years were also reviewed. Special interest was taken in the types of
probes and substrates used (e.g., nanoparticle-based, nanorod-based, etc.), the type of
detection method (i.e., direct or indirect), and their performance in cancer diagnostics. Also
explained in detail in this chapter was PCA for its use in EV analysis in Chapters 3 and 4,
and an overview of machine learning and its various techniques was given.
The third chapter of this thesis was focused on the characterization of EVs derived from
BM- and Panc-MSCs, which are used in therapeutic applications (i.e., regenerative
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medicine). The SERS platform consisted of gold nanohole arrays of various size (100 –
1000 nm) and shape (triangles, circles, squares) and were fabricated by EBL. The nanohole
arrays provided LSPR modes around 650 – 690 nm and 750 – 780 nm. For SERS analysis,
the arrays were best matched with a 785 nm excitation wavelength laser. SERS spectra for
each EV group were reported and characterized. PCA was used initially to elucidate trends
in the EV groups and to explore the discriminatory power of the platform. While PCA was
able to determine the peaks responsible for most variance in the data set, it did not perform
well in classification tasks. Thus, various machine learning methods were explored, using
the PCs as inputs, to classify the BM- and Panc-MSC EVs. The optimal machine learning
algorithm determined for this data set was logistic regression, which could classify the EVs
with 89 % accuracy, 89 % sensitivity, and 88 % specificity.
The fourth chapter of this thesis explored ovarian cancer diagnosis via SERS
characterization of cancer-derived EVs. The gold nanohole arrays presented and
characterized in Chapter 3 were used again for EV trapping and SERS analysis. EVs
derived from two established OvCa cell lines (OV-90 and OVCAR3) and two primary
OvCa cell lines (EOC6 and EOC18) were investigated. As a normal control, EVs derived
from one human immortalized ovarian surface epithelial cell line (hIOSE) were used. PCA
was used again to provide insight to the compositional differences among the EVs, and as
expected, failed at classification tasks as observed in Chapter 3. However, the machine
learning algorithms tested in this chapter performed much better at EV classification using
this data set than that from Chapter 3. The logistic regression-based algorithm again
performed the best out of the various models tested. The model was used to classify four
sets of data, which contained (1) normal and established cell line-derived EVs, (2) normal
and high-grade cancer (EOC6) EVs, (3) normal and low-grade cancer (EOC18) EVs, and
(4) high- and low-grade cancer EVs. The accuracies, sensitivities, and specificities
achieved with such models ranged from 99.0 – 99.4 %, 98.1 – 100 %, and 99.0 – 100 %,
respectively. Therefore, there is great potential in using this methodology for ovarian
cancer diagnosis in a clinical setting.
While EVs were successfully characterized using nanohole array substrates, there are many
areas of this project that could be expanded on and further investigated. Of course, before
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such a methodology could be used in a clinical setting, the platforms must be tested with
clinical samples from cancer patients and healthy individuals. Samples from such patients
would be gathered in a non- or minimally-invasive fashion (e.g., blood, saliva, urine, etc.).
However, since these arrays are unfunctionalized, they are unable to specifically capture
EVs from cancerous sources. Therefore, at the moment, analysis would require prior
isolation of EVs from the samples rather than direct detection. There are also areas of
fabrication that could be further developed and optimized, ranging from the
nanofabrication technique, to device functionalization, to implementation in a microfluidic
device.
Nanofabrication by EBL is advantageous in that patterns are easily customizable, which is
especially useful in research to determine optimal device dimensions and conditions.
However, EBL is a very time-consuming and low-throughput process compared to other
nanofabrication techniques.[1] Fortunately, once device parameters are optimized, EBL can
be used to fabricate a mask that can be used in higher-throughput photolithography, which
has been applied for nanohole array fabrication in literature.[2,3] The photolithography
mask, which contains a master pattern, consists of opaque features (e.g., chrome-based) on
a transparent substrate (e.g., quartz).[4] The principles of photolithography and EBL are
very similar, but the former usually uses ultraviolet (UV) light in the 193 – 436 nm range
to induce changes in the resist while the latter patterns the resist with an electron beam
(Figure 5-1A).[1] Since each feature is exposed at the same time during photolithography,
patterns can be written much faster than in EBL, in which features are written one at a time.
Photolithography can be achieved by contact, proximity, or projection printing. While the
most commonly used photolithographic methods are contact and proximity printing for
highest throughput, they offer only moderate resolution with a minimum feature size
around 2 – 3 μm.[5] For EV trapping and sensing applications where smaller features are
required, projection printing is best-suited, which allows for resolution as small as 37 nm
while still maintaining high throughput.[6] Unlike contact and proximity printing for
photolithography, projection printing requires a sophisticated optical lens system to project
a deep-UV pattern from an excimer laser, usually of 193 nm or 248 nm wavelength (Figure
5-1B).[7] For comparison, a wafer with a diameter of approximately 7.62 cm can be
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completely exposed in less than 1 minute with photolithography,[5] while a 50 μm × 50 μm
patch of nanohole arrays made for this thesis required 1 – 2 minutes of exposure time with
EBL. Photolithography would allow for the rapid and mass production of nanohole arrays,
which would be ideal for clinical translation of the methodology, and warrants exploration.

Figure 5-1: (A) Schematic illustration comparing photolithography, with proximity
printing shown as an example, and EBL for nanohole array fabrication. (B)
Schematic illustration of photolithography by projection printing.
Unfunctionalized arrays are advantageous in that rich, heterogeneous biological spectra
can be investigated, but a clinical diagnostic setting may benefit from a more specific and
efficient capture technique. SERS probes and platforms have been functionalized with
cysteamine in literature, which allows for more efficient EV trapping via electrostatic
interactions between the cationic cysteamine and anionic EV membrane.[8,9] Cysteamine is
the simplest aminothiol and a degradation product of cysteine, which is inexpensive and
widely commercially available.[10] Cysteamine is able to anchor itself to gold surfaces
through its terminal thiol group. In an acidic solution (pH = 6.5), the terminal amine group
of cysteamine is expected to be protonated, thus allowing for electrostatic interactions with
EV surfaces as aforementioned.[10]
While cysteamine functionalization would allow for greater adhesion of EVs to the
platform, it is not specific to cancer-derived EVs. Therefore, another avenue that could be
explored for platform functionalization is immunocapture with antibodies. EpCAM is a
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protein that has been identified as a diagnostic and prognostic biomarker in many
carcinomas,[11] including ovarian cancer.[12] EpCAM has an overexpression rate of 55 % in
mucinous ovarian cancer and a 76 % overexpression rate in serous and endometroid
ovarian cancers.[13] The nanohole arrays could thus be functionalized with anti-EpCAM for
the more specific capture of ovarian-cancer derived EVs, and could be achieved by 1-ethyl3-(3-dimethylaminopropyl)carbodiimide (EDC) crosslinker chemistry (Figure 5-2).[14]
EDC crosslinking begins with activating carboxyl groups for the direct reaction with the
primary amines of the antibody. Since this carboxyl-containing molecule should be
immobilized onto the gold nanohole arrays, the acid should also contain a terminal thiol
(e.g., 3-mercaptopropionic acid). When EDC reacts with carboxylic acid groups, an
unstable intermediate (O-acylisourea) that can be displaced by nucleophilic attack from the
primary amines is formed.[15] However, since it is unstable in aqueous solutions, it is
recommended to introduce N-hydrosucciminide (NHS) or its water-soluble analog (sulfoNHS). The sulfo-NHS group of this intermediate can then rapidly leave following the
addition of amine nucleophiles, thus conjugating anti-EpCAM to the platform via a stable
amide bond.[15] Anti-EpCAM has even been used in the immunocapture of breast cancer[16]

and prostate cancer-derived EVs.[17] The platform could thus benefit from more specific

ovarian cancer-derived EV capture using anti-EpCAM, and it could also be tested with
EVs from other cancer sources.
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Figure 5-2: Schematic illustration of antibody functionalization by EDC chemistry.
Finally, once optimal fabrication and functionalization conditions are identified, the
platform can be embedded in a microfluidic device. A microfluidic device would allow for
the probing of EVs more similar to their native state (i.e., in liquid), rather than dry on the
platform, which can introduce unwanted salt formation. The analyte flow can be controlled
by a dielectric[18] or acoustic force.[19] Since EVs can be isolated and captured in the
microfluidic chamber by both size-based[20-22] and immunoaffinity-based methods,[23-25]
the nanohole arrays can be integrated either unfunctionalized, as was presented in Chapters
3 and 4, or functionalized, as proposed in this chapter. Microfluidics is of interest in the
precision medical field because it utilizes a small number of samples,[26] allows samples to
be recycled,[27] and can be used in various analysis methods, including SERS.[28]
The goal of this work is to develop a diagnostic device for the minimally-invasive, rapid,
and early diagnosis of cancer. The preliminary work presented in this thesis displayed the
potential of using gold nanohole arrays for cancer detection by SERS, but further tailoring
of the device and testing with clinical samples is required before the device can be used on
its own in real diagnosis applications. We hope that the work presented in this thesis will
one day translate to point-of-care cancer detection and diagnosis.
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Appendix A: Confusion Matrix Calculations
A confusion matrix is a representation of the classification performance of a given
algorithm (Table A-1).[1] There are four possible outcomes given a classifier and an
instance. If a positive instance is correctly classified as positive, it is counted as a true
positive (𝑇𝑃) outcome, but if it is misclassified as negative, it is counted as a false negative
(𝐹𝑁). If a negative instance is correctly classified as negative, it is counted as a true
negative (𝑇𝑁), but if it is misclassified as positive, it is counted as a false positive (𝐹𝑃).
Table A-1: Example confusion matrix.

Actual

Predicted
Positive

Negative

Positive

𝑇𝑃

𝐹𝑁

Negative

𝐹𝑃

𝑇𝑁

Sensitivity, which can also be referred to as recall, is a quantification of the true positive
rate and is calculated by:[2]
𝑇𝑃

𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 = 𝑇𝑃+𝐹𝑁

(A-1)

Conversely, specificity is a quantification of the true negative rate and is calculated by:[2]
𝑇𝑁

𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 = 𝑇𝑁+𝐹𝑃

(A-2)

Precision is a quantification of the positive predictive value of an algorithm and is
calculated by:[1]
𝑇𝑃

𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 = 𝑇𝑃+𝐹𝑃

(A-3)

Lastly, accuracy is the proportion of all the correct predictions among the total population
and is calculated by:[2]
𝑇𝑃+𝑇𝑁

𝑎𝑐𝑐𝑢𝑟𝑎𝑐𝑦 = 𝑇𝑃+𝐹𝑁+𝐹𝑃+𝑇𝑁
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